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Cancer development is frequently linked to signaling pathways that are required for normal 
embryonic patterning. One of the pathways important in patterning and growth of the embryo 
is the Hedgehog (Hh) signaling cascade. Activation or inappropriate maintenance of this 
pathway in the adult organism is frequently caused by mutations in the Hh receptor Patched 
(Ptch) or overexpression of Hh and can result in the development of a variety of tumors. 
Whereas the pathway’s function in tissues such as skin, brain, lung, muscle, bladder, breast 
and prostate is well studied, the knowledge about its role and tumorigenic potential in cells 
composing the immune system is very limited. The original goal of this thesis was to 
elucidate the function of Ptch in macrophages. For this purpose Ptch
flox/flox 
mice were crossed 
with LysMcre mice. The latter mice express a cre recombinase specifically in lysozyme M 
(LysM) positive cells that are mainly macrophages, granulocytes and dendritic cells (DC), 
which are derived from the myeloid lineage.  
Surprisingly, the Ptch mutation in LysM positive cells resulted in multiple tumors arising 
from the wall of the stomach or the intestine. In the tumors Hh signaling was activated. 
Furthermore the histology, localization, responsiveness to imatinib, and molecular analysis 
were suggestive of Gastrointestinal Stromal Tumors (GIST). Because human GIST are 
considered to arise from KIT- or PDGFRA-expressing cells of the smooth muscle layer of the 
GI tract, this observation was inconsistent with the Ptch mutation in the myeloid lineage. To 
resolve this discrepancy, a lineage tracing experiment was performed. The data showed that 
the tumors indeed arose from LysM-expressing cells. In addition, these cells were Kit-
negative and sometimes expressed Pdgfrα. Similar relationships of Kit and Pdgfrα expression 
were found in the GIST-like tumors, which were all negative for Kit, but highly expressed 
Pdgfrα. Since HH- and PDGFRA, but not KIT-signaling pathways cooperated in oncogenic 
transformation, the data suggest that the GIST-like tumors in Ptch mutant mice developed 
due to the cooperativity between Hh and Pdgfrα pathways from Kit-negative cells in the 
intestine. 
 
In addition, the function of Ptch-deficient macrophages was analyzed. First, the response to 
inflammatory stimuli was investigated. For this purpose, bone-marrow derived macrophages 




animals and were challenged with 




that Ptch was important for IL-6 expression and macrophage proliferation after BLP 
stimulation. 
Second, in order to study the role of Ptch-deficient macrophages (and other myeloid cells) in 










and respective control mice. The analysis revealed that the Ptch-
deficiency had no impact on primary or metastatic tumor growth. Similar observations were 
made after i.p. injection of the slow-growing ovarian carcinoma cell line ID8-LUC and 





control mice were subjected to the two-stage chemical carcinogenesis DMBA/TPA protocol, 
which results in the development of papilloma and melanoma-like nevi. Whereas papilloma 





animals which were associated with a stronger infiltration with skin 
macrophages. Taken together, these results suggest that Ptch-deficiency in LysM-expressing 







2.1 Key components of the Hedgehog signaling pathway 
 
Many components of the Hh signaling cascade were initially described by the two Nobel 
laureates, Nüsslein-Volhard and Wieschaus, in 1980. In their systematic search for embryonic 
patterning in mutant Drosophila melanogaster, Nusslein-Volhard and Wieschaus identified 
15 loci which, when mutated, altered the segmental pattern of the larva 
1
. For example, they 
observed mutant larvae that failed to develop the naked posterior part of each segment and 
showed duplication of the anterior denticle band. Since the mutant larvae were almost 
entirely covered with denticles leading to a 'hedgehog-like' appearance, the responsible gene 
was named Hedgehog (Hh). Besides the Hh gene, they also identified other genes, which 
later turned out to be key components of the Hh signaling pathway 
1
. These genes included 
the Drosophila Hh receptor Patched (Ptch), the kinase fused (fu), and the downstream 




In mammals three Hh homologs have been identified. These are Sonic (Shh), Desert (Dhh), 
and Indian hedgehog (Ihh). In addition, one smo (Smo), two ptc (Ptch1 and Ptch2) and three 
ci homologues (Gli1, Gli2 and Gli3) have been discovered. The expression and function of 
Ptch1 (referred to as Ptch from here on) is similar to that of D. melanogaster ptc. The 
expression of Ptch2 is more restricted than Ptch, and it may have distinct functional 




All three Hh homologs play a role in developmental patterning. In vertebrates, Shh has been 
shown to regulate patterning of the developing limb bud, the axial mesoderm, and the neural 
tube 
4, 5
. Moreover, disruption of Shh in mice results in midline defects such as cyclopia and 
absence of the spinal column and most of the ribs 
6
. Ihh has been reported to play a major role 
in chondrocyte maturation and skeletal development 
7
, while Dhh has been shown to regulate 




Figure 1 shows a simplified model of the Hh signaling pathway in vertebrates. In the absence 
of the Hh ligand, the signaling pathway is maintained inactive by the 12-transmembrane-
domain receptor protein Ptch. Normally Ptch is concentrated at the base of the primary 




cell types and functions as a signal transduction compartment 
9
. Ptch blocks the activity of the 
7-transmembrane-domain protein Smo, which is a positive regulator of the Hh signaling 
pathway 
10
. The exact mechanism of Smo inhibition by Ptch is not well understood, but is 
probably caused by sterols, which can be secreted by Ptch 
11
. Hh signaling activation occurs 
when the secreted Hh ligand binds to Ptch. The interaction of Hh with Ptch removes Ptch 
from the primary cilium, thus allowing Smo to translocate to the primary cilia. There it 
transduces downstream signals to activate the Gli family of transcription factors by 
promoting the dissociation of the Suppressor of fused (Sufu) from the Sufu/Gli complex. This 




There are three members of the Gli family in vertebrates, which are Gli1, Gli2 and Gli3. Gli3 
exists in two forms: these are the full-length Gli3 form, capable of activating transcription in 
some systems (GliA), and a shorter (due to a truncated amino-terminal fragment) form that 
mediates the major role of Gli3 as a transcriptional repressor (GliR). In contrast to Gli3, Gli2 
is mainly a transcriptional activator 
12
. Activation of Gli2 and Gli3 leads to the transcription 
of Gli1, which further amplifies the initial Hh signal at the transcriptional level. Thus, the 
mRNA level of Gli1 is considered a reliable indicator of the pathway’s activity. Another Hh 




Figure 1. Simplified scheme of the Hh signaling pathway. The figure shows the interactions between the 
major components of the pathway. In unstimulated cells (left), the activity of the transmembrane protein Smo is 
suppressed by the Hh receptor Ptch (by blocking its translocation into the cilium). This keeps Gli attached to 
Sufu and in its repressive (GliR) form. In the presence of Hh ligands (right), the binding of Hh to Ptch suspends 
the inhibition of Smo, thereby allowing Smo to translocate to the cilium. This results in stabilization of the Gli 
activator (GliA) forms, which are released from the Sufu/Gli complex and translocated to the nucleus where 







The Hh pathway regulates the development of numerous tissues and organs 
15
. In the embryo, 
gradients of Hh are generated and, possibly in combination with other signaling factors, 
regulate apoptosis, proliferation, and differentiation of cells. This signaling is controlled in an 
area-specific and time-dependent manner 
16
. 
Hh signaling also remains active, albeit limited, throughout adult life. In adults it plays a key 
role in the maintenance and expansion of stem cell populations through modulation of their 




In summary, precise control of the onset, strength, and termination of Hh signaling is a 
critical requirement for proper pattern formation, morphogenesis, cell proliferation, survival, 
and differentiation (reviewed in 
18
). 
2.2 Models of Hedgehog pathway activity in cancer  
 
Cancer remains one of the leading causes of mortality and morbidity throughout the world 
19
. 
Although the different types of cancer may have a different cellular origin, all cancers share 
the same fundamental features characterized by the acquisition of the following hallmarks 
that determine tumor development, progression, and metastasis 
20
: self sufficiency of growth, 
unlimited replicative potential, activation of anti-apoptotic programmes, insensitivity to anti- 
growth factors, sustained angiogenesis, tissue invasion and metastasis. All these hallmarks 
determine tumor development, progression, and metastasis and can be directly or indirectly 
regulated by signaling cascades initiated by extracellular cues and signaling molecules 
20
. 
One of these signaling cascades is the Hh signaling pathway.  
 
Abnormal Hh signaling in cancer can be categorized as Hh ligand-dependent or ligand-
independent. The ligand-dependent mode of aberrant Hh signaling is subdivided into 
additional mechanisms. These are a) ligand-dependent autocrine signaling, which means that 
Hh is both produced and responded to by the same tumor cell, and b) ligand-dependent 
paracrine signaling which means that Hh produced by the tumor cells and signals to the 
stroma or c) “reverse paracrine” signaling, whereby Hh is secreted from stromal cells to 
receiving cells in a tumor (for review see ref 
21
). Examples of ligand-dependent tumors 
include tumors of the digestive tract (including those of the esophagus, stomach, biliary tract 
and pancreas) 
22




 and brain 
25















In contrast, ligand-independent mechanisms of Hh-activity in cancer are mutation-driven. 
This was initially shown in humans suffering from Gorlin syndrome (also known as basal cell 
nevus syndrome) 
30
. Patients with Gorlin syndrome show somatic mutations of PTCH 
30
 
which lead to constitutively active HH signaling in the absence of the HH ligand. Affected 
individuals develop multiple basal cell carcinomas (BCC) as well as medulloblastomas (MB) 
and other tumors including rhabdomyosarcomas (RMS) 
31
. In recent years it became obvious 
that more than 85% of cases of sporadic BCC are also due to inactivating PTCH mutations, 
whereas a smaller portion can be caused by activating mutations in SMO. Furthermore, 
inactivating PTCH or SUFU mutations have been detected in approximately 25% of sporadic 
MB, which is pediatric cancer of the cerebellum 
32, 33
. Similarly, RMS, which is a tumor of 
the skeletal muscle in children, has been associated with loss of heterozygosity of the PTCH 




The discovery of small molecule antagonists of SMO inhibitors such as cyclopamine has 
opened up exciting new prospects for molecularly targeted therapies of human cancers 
associated with Hh signaling. This potential has been tested in many mouse models and cell 
lines. For example, cyclopamine is effective in inhibiting the Hh signaling pathway and the 













 and pancreas 
40
 both in vitro and in vivo. Furthermore, oral cyclopamine has shown 
efficacy in endogenously developing tumors in mice. Thus, cyclopamine can block the 
growth of UV-induced BCC in Ptch
+/−
 mice by 50% 
35
. Furthermore, cyclopamine treatment 
in this mouse model prevents formation of BCC, implying a potential use of cyclopamine for 
BCC prevention. In addition, cyclopamine administration reduced BCC, but not squamous 
cell carcinomas (SCC) or fibrosarcomas that do not show activation of Hh signaling, 
highlighting the specificity of cyclopamine for the Hh pathway 
35
. Similarly, intraperitoneal 







recent years other more potent synthetic SMO inhibitors, such as vismodegib (GDC-0449) 
from Curis/Genentech, have been developed. Vismodegib is an orally available small-
molecule inhibitor of HH signaling, which was recently approved by the U.S. Food and Drug 






although the toxicity of vismodegib is generally not severe, the chronic nature of side effects 
frequently leads to discontinuation of therapy in almost half of the patients 
42
. 
2.2.1  Role of Hh signaling in gastrointestinal stromal tumors (GIST) 
 
Hh signaling is involved in many types of tumors (see above). However, its role in the 
pathogenesis of gastrointestinal stromal tumors (GIST) remains obscure. Because GIST is a 
major subject of this thesis, I will give a short introduction to this tumor entity here: 
 
GIST are the most common mesenchymal tumors of the gastrointestinal tract 
43, 44
. GIST are 
most frequently found in the stomach or small intestine, but can arise anywhere in the 
gastrointestinal tract and are occasionally found in the omentum, peritoneum and mesentery 
43
. Until recently, most GIST were classified as smooth muscle tumors. Based on 
histological data and immunoreactivity these tumors, which show almost no smooth muscle 




Data about Hh signaling in GIST are rare. However, a recent immunohistochemical analysis 
showed that HH, GLI1, and PTCH are overexpressed in a fraction of human GIST 
46
. 




. Together with the 
observation that HH expression correlates with the grade of GIST risk category and size 
46
, 
these findings suggest that HH signaling may play a role in the biology of this tumor entity. 
 
In contrast, constitutive activation of either the KIT or PDGFRA receptor tyrosine kinase 
(RTK) by oncogenic mutations plays a central pathogenetic role in GIST. Indeed, 
identification of these mutations eventually led to the acceptance of GIST as a separate 
tumor entity from its nearest histological relative, leiomyosarcomas (LMS) 
48, 49, 50
. Based on 
their sequence homology and similar conformational structure, KIT and PDGFRA belong to 
the same class (III) of RTK. Whereas PDGFRA is stimulated by its ligands PDGFA, 
PDGFB and PDGFC (but not PDGFD) 
51
, the only known ligand for KIT is the stem cell 
factor, SCF. The KIT ligand is constitutively produced by some endothelial and stromal cells 
in the bone marrow, spleen, lymph nodes, and thymus of adults (reviewed in 
52
). The KIT 
receptor plays a critical role in the normal development and function of the interstitial cells 
of Cajal (ICC). Thus, KIT is expressed by ICC 
53
. In addition, inactivating mutations in Kit 




that show intestinal pacemaker activity in mice 
54
. Because GIST are located in the 
muscularis propria in association with the myenteric plexus and because GIST frequently 




In GIST, the majority of the activating KIT mutations (70–75%) have been found in the 
juxtamembrane domain in a hotspot region at the 5′ end of exon 11 involving codons 550–
560 
56
. By analogy with other RTK, the juxtamembrane domain may function as a negative 
regulator of the KIT kinase. Disruption of the conformational integrity of this domain may 
impair its negative regulatory function. Thus, the oncogenic potential of the juxtamembrane 
domain mutations is attributed to the loss of this inhibitory function. A second, less common 
hotspot in the juxtamembrane domain is located at the 3′ end of exon 11 
56
. Activating KIT 
mutations in the hotspot regions do not appear to be associated with a specific 
clinicopathologic phenotype, but the presence of deletions rather than substitutions predicts a 
more aggressive tumor behavior. Exon 9 mutations occur in 10–15% of GIST patients with 
KIT mutation and comprise a distinct subset of GIST that are often located in the small 
bowel and show more aggressive behavior 
56
. In contrast to the more common KIT 
mutations in exons 9 and 11, mutations have been rarely described in the KIT kinase domain 
(exons 13 and 17) 
57





Approximately 15% of GIST show no activation of KIT. Half of these cases show activating 




. The most common PDGFRA 
mutation (63%) is the D842V substitution in exon 18 
59
. Many PDGFRA mutant GIST 
express PDGFRA, show a preference for gastric location, epithelioid morphology and a 
variable or absent KIT expression by immunohistochemistry (IHC). In addition, these 
tumors are relatively benign 
58
. In approximately 10% of GIST patients, mutations in neither 
KIT nor PDGFRA have been identified. In particular, most GIST in children are wild type 




At present, it is unclear if PDGFRA-positive GIST arise from ICC in which KIT expression 
has been turned down, or from different cells. In support of the latter possibility, KIT-
negative but PDGFRA-positive fibroblast-like cells have been found in association with ICC 
and nerve bundles 
61-63
. On the other hand, Bardsley and colleagues reported PDGFRA-




cells and form tumors in nude mice 
64
. However, unlike GIST, these tumors are resistant to 
imatinib, a drug that targets the kinase-activity of both KIT and PDGFRA 
65
, and their 
significance to in situ (i.e. gastro-intestinal) GIST formation is unclear.  
2.3 The role of Hedgehog signaling in immune cells 
2.3.1 Hematopoiesis 
 
The establishment and maintenance of the hematopoietic system relies on self-renewing 
hematopoietic stem cells (HSC) that normally reside in small numbers in the bone marrow 
niche of adult mammals. HSC divide to form more HSC (self-generation) or to form cells 
committed to the generation of either myeloid cells (common myeloid progenitors, CMP) or 
lymphoid cells (common lymphoid progenitors, CLP). CMP are large blast cells that give rise 
to the more restricted i) granulocyte-macrophage progenitors (GMP) able to generate 
monocytes, macrophages, and granulocytes (neutrophil, eiosinophil and basophil) and ii) 
megakaryocyte-erythroid progenitors (MEP) committed to the formation of erythroid and 
megakaryocytic progeny (reviewed in 
66
). CLP give rise to NK cells, T and B cells (Figure 2).  
 
 
Figure 2 HSC and derived haematopoietic cell lineages. HSC: hematopoietic stem cells; CMP: common 
myeloid progenitor; CLP: common lymphoid progenitor; GMP:granulocyte-monocyte progenitor; MEP: 
megakaryocyte-erythrocyte progenitor. Figure adapted from 
67
. 
2.3.2 The innate immune system 
 
The innate immune system comprises the first line of host defense during infection and 
therefore plays a crucial role in the early recognition and subsequent triggering of a pro-




hand, is responsible for elimination of pathogens in the late phase of infection and in the 
generation of immunological memory. Whereas the adaptive immune response is 
characterized by specificity developed by clonal gene rearrangements from a broad repertoire 
of antigen-specific receptors on lymphocytes, the innate immune response can be mediated 
by phagocytic cells such as granulocytes, macrophages, and DC, and has been regarded as 
relatively non-specific 
68





The innate immune response relies on a large family of pattern recognition receptors such as 
Toll-like receptors (TLR). TLR can trigger intracellular signaling cascades ultimately 
culminating in the expression of a variety of pro-inflammatory molecules, which together 
orchestrate the early host response to infection, and also are a prerequisite for the subsequent 
activation and shaping of adaptive immunity. In order to avoid a pathologic immune 
response, this system is tightly regulated by a number of endogenous molecules that limit the 
magnitude and duration of the inflammatory response 
68
. Generally, TLR can regulate 
leukocyte recruitment to sites of infection by activating several cell type subsets, including 
tissue stromal cells, tissue-resident innate cells (most notably DC and macrophages), and 
circulating leukocytes. During acute inflammation, the cellular infiltrate consists of 
monocytes, DC, neutrophils, and NK cells. Among these, neutrophils and NK cells are 





The link between inflammation and cancerous tumors has long been recognized. 
Experimental, clinical and epidemiological studies have revealed that inflammation 
contributes to tumor progression and even predisposes to different types of cancer. 





. These macrophages have a distinct capability to express different 
cytokines, chemokines and growth factors in response to different microenvironmental 
signals, which typically manifest themselves in pathological conditions such as infections and 
cancer. The balance between the phenotypic roles played by the macrophages in cancer is 
critical to its promotion or suppression. In response to cytokines and microbial products, 
mononuclear phagocytes express specialized specific genes resulting in characteristic 




The “classically” activated M1 macrophages are induced by IFN-γ alone or by microbial 
stimuli (i.e. LPS and BLP). By releasing high levels of cytokines such as TNFα, IL-6 and 
IL12 
72
, M1 macrophages have cytotoxic ability toward tumor cells as well as toward cells 
that have ingested intracellular microorganisms. M1 macrophages are generally considered as 
potent effector cells, which defend the body against the attack of pathogens and tumor cells.  
On the other hand, the “alternatively” activated M2 macrophages function as suppressors of 
inflammatory responses 
70
. Tumor-associated macrophages share many characteristics with 
M2 macrophages in that they express the Triggering receptor expressed on myeloid cells-2 
(Trem2) 
73
, Resistin-like molecule α (Rlmα or Fizz1) 
74
 and Arginase 1 (Arg1) 
75
. Many 
experiments indicate that, in the tumor microenvironment, tumor-associated macrophages 
have several protumoral functions which are more similar to M2 macrophages, including 
expression of growth factors and matrix proteases, promotion of angiogenesis and 
suppression of adaptive immunity 
70
. 
2.3.3 Hh signaling in immune cells 
There have been several studies on the role of Hh signaling in embryonic development and 
tissue patterning. However, the knowledge about its role in hematopoeisis and in the immune 
system is sparse. Bhardwaj and colleagues provided evidence that Hh proteins play a 
functional role in the development of human blood cells. They showed that SHH, PTCH, 






 stem cells isolated from human blood 
and also in cells comprising the haematopoietic microenvironment such as BM stromal cells. 







 (T) cell populations. Since the downstream 
transcriptional regulators of the HH pathway, GLI1-3 were not expressed in lineage restricted 
hematopoietic cells, the authors concluded that HH signaling is not essential to hematopoietic 
cell maturation. However, the authors found that blocking of endogenously produced HH or 
addition of exogenous soluble HH controlled the proliferation of uncommitted human 
hematopoietic cells. This showed that HH signals are critical to the proliferative regulation of 
hematopoietic progenitor cells and that HH is capable of regulating primitive blood cells and 
inducing human stem cell expansion 
76
. Moreover, HH pathway activation is involved in the  







2.3.3.1. Hh signaling and the lymphoid lineage  
 
SHH and its receptor PTCH are also expressed on resting and activated human peripheral 
CD4
+ 
cells. Therefore it has been hypothesized that HH signaling may control the effector 
function of mature T lymphocytes. Indeed, in vitro experiments showed that the addition of 
exogenous SHH increased the production of IL-2, IFN-γ, and IL-10 in activated CD4
+
 T cells 
77
. Furthermore, addition of Shh significantly enhanced proliferation of anti-CD3/28 Ab-
activated CD4
+ 
T cells by promoting the entry of the cells into the S-G(2) proliferative phase 
of the cell cycle and not by anti-apoptotic effect 
78
. Finally, endogenously produced Shh may 
also play a physiological role in the clonal expansion of murine T cells 
79
. On the other hand, 
depletion of Ptch in mature T cells (which likewise should result in activation of Hh 
signaling) did not result in a definite defect of T cell function (Kai Michel et. al, manuscript 
in review). 
 
Shh is not expressed by B cells in the germinal centers (GC), which are sites within lymph 
nodes where mature B lymphocytes rapidly proliferate and differentiate and produce their 
antibodies during a normal immune response to an infection. However, the follicular DC 
surrounding the B cells in GC strongly express Shh, which may transduce the signal to the 
neighboring B cells. Indeed, all B cells in GC express the Hh receptors Ptch and Smo and 
thus are capable of binding Hh proteins at their cell surface. Therefore, a fraction of these 
cells is probably capable of transducing the Hh signal into the cell. Indeed, inhibition of the 
Hh pathway by the addition of cyclopamine or anti-Shh mAb reduces the survival, and 
consequently the proliferation and immunoglobulin secretion of B cells in GC. Inversely, 




An interaction of B cells with HH produced by stromal cells is also evident in B cell 
malignancies 
81
. Thus, infiltrating lymphoma cells in the spleen and BM of transgenic Eμ-
Myc mice expressed Gli1, Gli2 and Smo, whereas the surrounding DC, the mesenchymal 
stem cells as well as splenic stromal cells expressed Hh ligands, which function as survival 
factors for the tumor cells. This effect of stromal HH was the same on lymphoma and 
plasmocytoma cells isolated from humans with these malignancies. Furthermore, a blockage 
of Hh signaling in vivo inhibited expansion of mouse lymphoma cells and reduced the tumor 
mass in mice with fully developed disease. Therefore, stromally induced Hh signaling may 






Hh signaling also seems to be involved in T and B cell lineage commitment. The first hint 
came from the study by El Andaloussi and colleagues. Using pre-T cell-specific, mature T 
cell-specific and ubiquitous deletion of Smo in mice, the authors reported that Hh is an 
essential positive regulator of T cell progenitor differentiation. Furthermore, their data 
localized Hh function to a stage preceding pre-T cell receptor signaling 
82
. By inducibly 
abrogating Ptch expression in mice, our group then demonstrated that Hh signaling in stromal 
cells is mandatory for the specification of both B and T cell lineages at the CLP stage in the 
BM 
83
. This was revealed by ubiquitous Ptch inactivation in the adult animal. Ptch mutant 
mice showed thymic atrophy and a defective T and B cell development, which was probably 
due to the loss of Ptch function in the stromal cell compartment.  
2.3.3.2. Hh signaling and the myeloid lineage  
 
The data about the role of HH signaling in cell subsets derived from the myeloid lineage is 
sparse. Detmer and colleagues demonstrated that HH signaling might be one of the 
mechanisms in the regulation of proliferation and differentiation of erythroid progenitor cells 
in vitro 
84,85
. In addition, there is evidence that HH signaling may influence processes 
involved in myeloid leukemia, because HH signaling was activated in Bcr-Abl-positive 
leukemic stem cells via upregulation of SMO. In addition, in vitro, inhibition of HH signaling 
using cyclopamine induced apoptosis in Bcr-Abl-positive cells 
26
. Vice versa, mouse 
experiment showed that loss of Smo and pharmacological inhibition of Hh signaling using 
cyclopamine impaired the induction and the propagation, respectively, of Bcr-Abl-associated 
chronic myelogenous leukemia (CML) by causing depletion of CML stem cells 
86
. Finally, 
the chemotherapy-resistant phenotype of myeloid leukemia cells was recently correlated with 
activation of HH signaling, whereas in chemosensitive cells such activation was less 
pronounced 
87
. These data indicated that Hh pathway activity is required for maintenance of 
normal and CML stem cells 
86
 and also plays a role in response of leukemic cell lines to 
chemotherapy.  
In contrast, our group did not observe CML or other blood-related malignancy when Ptch
 
was 
conditionally inactivated in mice 
83
. In addition, the Ptch mutation had no effect on the 
differentiation of multipotent clonogenic myeloid progenitors into granulocytes, erythrocytes, 
megakaryocytes or macrophages. This difference to the above-mentioned data may have been 
caused by an incomplete loss of Ptch (both in the BM stroma and myeloid lineage) after 




It is known that human CD33
+
 (myeloid) cells express components of the HH pathway such 
as PTCH and SMO but lack the expression of GLI1-3 
76
. About 80% of macrophages in 
human aortic atherosclerotic lesion are also express PTCH. Furthermore, monocytes express 
IHH and DHH but not SHH or GLI1-2. Both SHH and IHH induce migration of human 
monocytes ex vivo in a concentration-dependent fashion 
88
. Furthermore, Pereira et. al 
showed that macrophages in liver of patients infected with schistosoma can produce IHH and 
SHH and adopt a M2 phenotype. The authors also showed that exposure of murine 
macrophages to schistosoma egg antigen not only resulted in increased expression of Gli and 
Ptch, but also in increased expression of the M2 markers Arg1 and Fizz1. The schistosoma 
egg antigen-induced expression of the M2 markers and of Gli and Ptch was inhibited after 
treatment of cells with the Smo inhibitor GDC-0449 
89
. In contrast, exposure of murine 
macrophages with LPS did not lead to any significant change in Ihh, Gli1 or Ptch expression. 
Together, these data suggest a role of Hh signaling in the function of more mature cell 
subsets derived from the myeloid lineage, i.e. macrophage, granulocytes or DC. 
2.4 Patched knockout mice: A model to study the function of Hh signaling in cancer 
and immunity 
 
Experiments in various mouse models have enormously improved our knowledge about Hh 
signaling not only in cancer but also in the immune system (see above). These models include 
transgenic Smo and Sufu or Ptch knockout mice (reviewed in 
90
). In the present work, we 
applied a conditional mouse model of Ptch-deficiency (Ptch
flox
) to investigate the role of Hh 
signaling in LysM positive cells.  
The conditional knockout Ptch
flox / flox
 mouse model was generated by flanking exons 8 and 9 
of the Ptch gene by loxP sequences 
83
. The respective loxP sites are localized in introns 7 and 
9. The loxP sites are recognized by the cre recombinase enzyme resulting in site-specific 
DNA recombination and the deletion of the loxP-flanked gene sequence in targeted tissues. 
The conditional Ptch knockout mouse has several benefits over the conventional knockout 
type. Thus, the homozygous Ptch deletion in conventional knockout mice results in 
embryonic lethality at d9.5 – d10.5 and impedes the investigation of effects of a biallelic Ptch 
knockout in the adult. In conditional knockout mice, the Ptch gene can be deleted in a time- 
and tissue-specific manner. In addition, the gene can be deleted mono- or biallelically both in 




crossing mice with a floxed allele to mice expressing the cre recombinase under a tissue-
specific promotor.  
As reported by our group, Ptch
flox/flox
 mice are born at the expected Mendelian ratio and are 
viable and fertile. Neither the loxP sites nor the neomycin resistance cassette in intron 9 
disturb the normal splicing of the Ptch mRNA derived from the Ptch
flox 
 allele. The excision 





. This results in an aberrant Ptch transcript with exon 7 spliced into exon 10. This leads to a 
frameshift and a premature stop codon. Similar to homozygous mutants observed in 
conventional Ptch knockout mice on the same genetic background, homozygous Ptch
del/del
 
mutants die before embryonic day 10 in utero while Ptch
del/+ 
mice survive. 
Our group has recently crossed Ptch
flox/flox
 mice with the Rosa26CreERT2 (ERT2) strain. 
ERT2 is a knock-in mouse expressing a tamoxifen-inducible cre recombinase under control of 
the endogenous Rosa26 promoter, which is ubiquitously active. Therefore, Ptch can be 




 offspring by injection of 
tamoxifen. This mouse model has been extensively used by our group to study the function of 








2.5 LysMcre mice: a tool for highly efficient cre-mediated deletion of loxP-flanked 
target genes in myeloid cells 
 
The antimicrobial, cationic protein Lys was identified as a major constitutive secretory 
product of mouse and human macrophages in culture 
95
. In humans, LYS is strongly 
expressed in tissue monocytes and macrophages in several tissues like the spleen, lungs, 
kidneys, stomach and small intestine. Other organs like parts of the brain, pancreas and skin 




In contrast to humans, who has one LYS gene 
97
, the murine genome encodes for two Lys 
genes. These are the LysM gene specific for myeloid cells and the LysP gene expressed in 
Paneth cells 
98
. The two murine genes evolve from a gene duplication event and thus share a 




. In mice, the highest LysM expression levels is found in lung 
and bone marrow, while weaker expression is detected in small intestine, spleen, and thymus. 




very high in mature macrophages 
100
. In addition to its constitutive expression in 
macrophages, up-regulation of LysM transcription is a marker of macrophage activation in 
murine tissues 
101
. It has been shown that ablation of the LysM gene in mice leads to an 
increased inflammatory response to bacterial infections due to impaired function of 
granulocytes and macrophages 
102





In LysMcre mice, the cre recombinase gene is inserted into the first exon of the LysM gene. 
When crossed with a reporter mouse containing a lox-P site-flanked cassette, excision was 
detected in myelomonocytic cells including macrophages and granulocytes. In contrast, no 
significant deletion was observed in tail DNA or purified T and B cells 
104
. Similarly, another 
study by Miyamoto and colleagues showed that virtually all myelomonocytic cells 
(granulocytes and monocytes) are LysM
+
. However, the authors also showed that LysM is not 
only expressed in myeloid progenitor cells but also in lymphoid progenitor cells, although at 
very low level. Thus, they found that 1–5% of CLP and Pro T cells expressed minimal levels 
of LysM 
67
. In the myeloid pathway, 62% of CMP expressed significant levels of LysM
 
while 
GMP expressed a 5-fold increase of LysM compared to CMP. A lineage tracing experiment 
further showed that besides macrophages (85.9 ± 4.0%,) also B cells (9.3 ± 3.9%,) and T cells 
(7.8 ± 3.9%) are derived from a LysM
+
 precursor cell. Indeed, a consecutive analysis of HSC 
revealed that 20% of HSC express LysM. These results demonstrate that LysM expression 
does not only mark myeloid cells but probably other cells. 
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3 Aim of the Study 
 
The primary aim of the study was to analyze and understand the function of the Hh receptor 





 mice. According to the literature, this should result in the Ptch 
deletion mainly in macrophages, DC and granulocytes. Surprisingly, when Ptch was 
inactivated in LysM-expressing cells, the animals developed tumors of the gastrointestinal 
tract. To characterize the tumors, in situ hybridization, immunohistochemistry, immunoblot, 
quantitative RT-PCR analyses, cell transformation assays and lineage tracing experiments 
using R26R-LacZ reporter mice were performed.  
Additional experiments were performed to get insight into the function of Ptch in myeloid 





 mice with/without stimulation with LPS or BLP was analyzed. 





 mice were either subjected to the two-stage chemical 
carcinogenesis DMBA/TPA protocol or were transplanted with syngeneic melanoma and 
ovarian carcinoma cells.  
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4 Materials and Methods 
4.1 Technical equipment  
 
Table 1. List of laboratory equipment. 
Equipment  Supplier 
-80°C Freezer(MDF-U71V) Sanyo Electric Co., Ltd., Japan 
Agarose gel electrophoresis chamber Peqlab Biotechnologie GmbH, Erlangen 
Agilent 2100 Bioanalyzer Agilent Technologies, Waldbronn 
Autoclave W. Krannich GmbH & Co. K.G., Göttingen 
Incubators Kendro Laboratory Products GmbH, Hanau 
Crosslinker (Crosslinker CL-1) Herolab GmbH, Wiesloch 
Digital Photo camera (PowerShot G2) Canon Inc., Japan 
Single channel pipettes Eppendorf, Hamburg 
Developing machine(Curix 60) AGFA Deutschland Vertriebsgesellschaft mbH 
& Co, Köln 
Weighing scale (Sartorius Basic plus) Sartorius AG, Göttingen 
Film cassette Sigma-Aldrich Chemie GmbH, Steinheim 
Gas burner (Gasprofi 2 scs) WLD-TEC GmbH, Göttingen 
Automated tissue processor (TP 1020) Leica Mikrosysteme Vertrieb GmbH, Bensheim 
Heat block (Thermomixer) Eppendorf, Hamburg 
Heating and stirring plate (MR 3000/3001) Heidolph Instruments, Schwabach 
Homogenizer (Miccra D-1) ART-moderne Labortechnik e.K., Müllheim 
Hybridization oven (HB-1000 Hybridizer) UVP, Inc., Upland, USA 
Inverse microscope with fluorescence filter (Axiovert 25, 
Filter Set 43, 01, 09) 
Carl Zeiss Jena GmbH, Jena 
Cryostat (Modell CM 1900-1-1) Leica Microsysteme Vertrieb GmbH, Bensheim 
MilliQ-water purifier MembraPure GmbH, Bodenheim 
Mini centrifuge Carl Roth GmbH, Karlsruhe 
Multipette Eppendorf, Hamburg 
Paraffin dispenser, embedding machine (Dispenser PAG 
12) 
Medite Medizintechnik GmbH, Burgdorf 
PCR machine Eppendorf, Hamburg 
PCR-machine (PrimusHT) MWG AG Biotech, Ebersberg 
PCR-machine (Robocycler Gradient 96 Combo) Stratagene, Amsterdam Zuidoost, Netherlands 
pH-Meter (inoLab pH Level 1) WTW GmbH, Vienna, Austria 
Photometer (Biophotometer 6131, Thermodrucker DPU-
414) 
Eppendorf, Hamburg, Germany 
Pipette controller(Accu-jet) Brand GmbH & Co. KG, Wertheim, Germany 
Microtome (HN 40) Leica Microsysteme Vertrieb GmbH, Bensheim, 
Germany 
Shaker New Brunswick Scientific GmbH, Nürtingen, 
Germany 
Shaking water bath (1083) GFL GmbH, Burgwedel, Germany 
Sequencing machine (ABI 3100) Applied Biosystems, Darmstadt, Germany 
Stereo microscope (Stemi 2000) Carl Zeiss Jena GmbH, Jena, Germany 
Clean bench (Euroflow Class IIA) Clean Air Techniek bv, Woerden, Netherlands 
Power source for electrophoresis Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
Liquid nitrogen tank L’air liquide S.A., Paris, France 
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TaqMan (ABI Prism 7900HT) Applied Biosystems, Darmstadt, Germany 
UV-printer(Digital Monochrome Printer P91D) Mitsubishi, Ratingen, Germany 
UV-Transilluminator/Software Intas, Göttingen, Germany 
Vacuum pump Schütt Labortechnik, Göttingen, Germany 
Vortexer (Vortex-Genie 2) Scientific Industries, Inc., Bohemia, USA 
Cell counter Omnilab-Krannich, Göttingen, Germany 
Centrifuges (Biofuge pico, fresco, primo, Multifuge 3L-
R) 
Kendro Laboratory Products GmbH, Hanau, 
Germany 
12 Channel-pipette Eppendorf, Hamburg, Germany 
4.2 Consumable materials 
 
Table 2. List of consumable materials. 
Consumer Goods Supplier 
1.5 ml microcentrifuge tubes Ochs GmbH, Bovenden/Lenglern, Germany 
13 ml tubes Nunc GmbH & Co.KG, Wiesbaden, Germany 
15 ml conical tubes Greiner Bio-One GmbH, Frickenhausen, 
Germany 
2.0 ml microcentrifuge tubes Sarstedt AG & Co., Nürnberg, Germany 
50 ml conical tubes Sarstedt AG & Co., Nürnberg, Germany 
Tissue Culture Plate (6-Well) Sarstedt AG & Co., Nürnberg, Germany 
Cleaning plate 96-well (MAHVN45) Amersham Biosciences Europe GmbH, 
Freiburg, Germany 
Blotting-Paper (GB 33 B003) Heinemann Labortechnik GmbH, Duderstadt, 
Germany 
Cover glass Menzel GmbH & Co.KG, Braunschweig, 
Germany 
Disposable pipette tips (Combitips plus) Eppendorf, Hamburg, Germany 
ECL-Film (Hyperfilm ECL) Amersham Biosciences Europe GmbH, 
Freiburg, Germany 
Disposable syringes (BD Plastipak) BD GmbH, Heidelberg, Germany 
Filter paper Schleicher & Schüll, Dassel 
Glasswares Schott AG, Mainz, Germany 
Disposable needles (Sterican Ø 0,45 x 12 mm) B. Braun Medical AG, Emmenbrücke, 
Germany 
Cryopreservation solution (Cryo.s) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cuvettes (UVette) Eppendorf, Hamburg, Germany 
96 Well Assay Plate (for luminescence measurement) Costar, Corning Incorporated, New York, 
USA 
Nitrocellulose membrane (Hybond-XL) Amersham Biosciences Europe GmbH, 
Freiburg, Germany 
Microscope slides (SuperFrost Plus) Menzel GmbH & Co.KG, Braunschweig, 
Germany 
2 well culture slides (Culture Slides) BD Falcon, Heidelberg, Germany 
Pasteur pipettes Brand GmbH & Co.KG, Wertheim, Germany 
PCR-reaction tube and lid (ThermoFast 96, non-skirted, 
natural domed cap strips, natural) 
Sarstedt AG & Co., Nürnberg, Germany 
Petri dish Ochs GmbH, Bovenden/Lenglern, Germany 
Pipette tips, with filter (10 µl, 100 µl, 200 µl, 1000 µl) G. Kisker GbR, Steinfurt, Germany 
Pipette tips, without filter (10 µl, 200 µl) Ochs GmbH, Bovenden/Lenglern, Germany 
Pipettenspitzen, ungestopft (1000 µl) Sarstedt AG & Co., Nürnberg, Germany 
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Serological pipettes (5 ml, 10 ml, 25 ml) Sarstedt AG & Co., Nürnberg, Germany 
Scalpel Aesculap AG & Co.KG, Tuttlingen, Germany 
Sterile filter Omnilab-Krannich, Göttingen, Germany 
96-Well Optical Reaction Plate, 384-well Optical Reaction 
Plate, Optical Adhesive Covers 
Applied Biosystems, Darmstadt, Germany 
Cell culture plates, 100 mm, 35 mm (Nunclon Surface) Nunc GmbH & Co.KG, Wiesbaden, Germany 
4.3 Reagents and Chemicals 
 
The chemicals not listed below were obtained from Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany. 
Table 3. List of chemical and reagents.  
Chemicals and Reagents Supplier 
1 kb DNA, 50 bp und 100 bp DNA Ladder Invitrogen GmbH, Karlsruhe, Germany 
Acetic anhydride Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Agarose Invitrogen GmbH, Karlsruhe, Germany 
BLP (Pam3CSK4)  InvivoGen San Diego, USA 
BM Purple Roche Diagnostics GmbH, Mannheim, 
Germany 
Boric acid ICN Biomedicals Inc., Aurora, USA 
Citric acid (monohydrate)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Cryoblock embedding medium Medite Medizintechnik GmbH, Burgdorf, 
Germany 
Deoxyribonucleotidtriphosphate (dNTP) Roche Diagnostics GmbH, Mannheim, 
Germany 
Diethyldicarbonate (DEPC) Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Dig RNA Labelling Mix, 10x conc. Roche Diagnostics GmbH, Mannheim, 
Germany 
Dulbecco's Modified Eagle Medium (DMEM) PAN Biotech GmbH, Aidenbach, Germany 
Eosin Y Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Ethylenediaminetetraacetic acid (EDTA) ICN Biochemicals Inc., Aurora, USA 
Fetal Calf Serum (or Fetal Bovine Serum) Gibco, Invitrogen GmbH, Karlsruhe, 
Germany 
Formamide, 99% DNase, RNase free Acros Organics, Geel, Belgium 
Glycer gel mounting medium Dako GmbH, Hamburg, Germany 
Horse serum (heat inactivatied) Gibco, Invitrogen GmbH, Karlsruhe, 
Germany 
Hydrogen peroxide, 30% Merck KGaA, Darmstadt, Germany 
I-Block (for antibody blocking buffer) Tropix, Bedford, USA 
Imatinib (Glivec) Novartis International AG, Basel, 
Switzerland 
Immuno Mount Shandon Thermo Electron Corporation, 
Waltham, USA 
Insulin Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Lipopolysaccharide (LPS, from E. coli, serotype O55:B5)  Enzo Life Sciences GmbH, Lörrach, 
Germany 
Ketanest S (25 mg/ml) Pfizer Pharma GmbH, Karlsruhe, Germany 
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Mayer's Hemalaun solution Merck KgaA, Darmstadt, Germany 
Mounting medium (Vectrashield Mounting Medium with 
DAPI) 
Vector Laboratories, Inc., Burlingame, USA 
Oligo(dT)-Nucleotide (50 ng/µl) Roche Diagnostics GmbH, Mannheim, 
Germany 
Paraformaldehyde Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
PBS tablets; ready to use solution GIBCO Invitrogen GmbH, Karlsruhe, 
Germany 
PDGF-BB (recombinant, human) R&D Systems, Wiesbaden-Nordenstadt, 
Germany 
Penicillin (10000 U/ml)/Streptomycin (10 mg/ml) PAN Biotech GmbH, Aidenbach, Germany 
Pertex mounting medium Medite Medizintechnik GmbH, Burgdorf, 
Germany 
Polyinosinic-polycytidylic acid (Poly I:C) Enzo Life Sciences GmbH, Lörrach, 
Germany 
Rapid-hyb Buffer Amersham Biosciences Europe GmbH, 
Freiburg, Germany 
Ringer-Lactate  B. Braun Melsungen AG, Melsungen, 
Germany 
RNAse-DNAse free water Invitrogen GmbH, Karlsruhe, Germany 
Rompun (2%) Bayer AG, Leverkusen, Germany 
RPMI 1640 Medium  PAN Biotech GmbH, Aidenbach, Germany 
Sephadexg-50 fine Amersham Biosciences Europe GmbH, 
Freiburg, Germany 
Sodiumdodecylsulfate (SDS) Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
TrypLE Express Gibco, Invitrogen GmbH, Karlsruhe 
TRIzol Invitrogen GmbH, Karlsruhe, Germany 
Tween-20 Scharlau Chemie S.A., Barcelona, Spain 
water (Ampuwa) Fresenius Kabi Deutschland GmbH, Bad 
Homburg, Germany 
WST-1 reagent Roche Diagnostics GmbH, Mannheim, 
Germany 
X-Gal Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Xylene J. T. Baker B.V., Deventer, Netherlands 
4.4 Kits and ready-to-use reaction systems 
 
All kits and ready-to-use reagents were used according to manufacturer's instructions.  
Table 4. List of ready-to use kits and reaction systems.  
Ready-to-use Kits and Reaction Systems Supplier 
Pierce ® BCA Protein Assay Kit  Thermo Fisher Scientific, Rockford, USA  
CD11b Microbeads Miltenyi Biotec, Cologne, Germany 
Cell Proliferation ELISA, BrdU (chemiluminescence)  Roche Diagnostics GmbH, Mannheim, 
Germany 
Dako REAL TM EnVision TM Detection System  Dako Denmark A/S, Glostrup, Denmark  
Enhanced chemoluminescence (ECL) Kit  Amersham Biosciences Europe GmbH, 
Freiburg, Germany 
PureLink HiPure Plasmid Midiprep Kit   Invitrogen GmbH, Karlsruhe, Germany 
QuantiTect SYBR Green PCR  Qiagen GmbH, Hilden, Germany 
RotiFect  Carl Roth GmbH & Co. KG, Karlsruhe, 




SYBR Green  Invitrogen Invitrogen GmbH, Karlsruhe, 
Germany 
4.5 Buffers and solutions 
 
Unless otherwise mentioned, all solutions were prepared using double distilled water 
(Sartorius AG, Goettingen).  
Table 5. List of buffers and solutions. 
AEC chromogen pH 5.2 30 mM Acetic acid 
70 mM Sodium acetate trihydrate 
16 mM 3-Amino-9 Ethylcarbazole (dissolved 
in dimethyl formamide) 
Boric acid pH 5.1 0.2 M Boric acid pH 5.1 
Citrate buffer pH 3.0 10 mM Sodium citrate pH 3.0 
Citrate buffer pH 6.0 10 mM Sodium citrate pH 6.0 
Cresol 0.1% (w/v) Cresol 
Saturated sucrose solution 
Denaturing buffer 1.5 M NaCl 
0.5 M NaOH 
Deoxyribonucleotide Triphosphate (dNTP-Mix) 10 mM dATP 
10 mM dTTP 
10 mM dGTP 
10 mM dCTP 
Eosin, 1% 1% (w/V) Eosin y (water soluble) 
80% (v/v) Ethanol 
Glutaraldehyde/1xPBS 0.2% (v/v) Glutaraldehyde 
1x PBS 
High-Stringency buffer 0.1% (w/v) Sodium dodecyl sulfate (SDS) 
0.2 x standard sodium citrate solution (SSC). 
pH 7.0 
Hybridization buffer 40% (v/v) Formamide 
10% (w/v) Dextran sulfate 
4x SSC pH 6.4 
1x Denhards 
LacZ-staining buffer 5 mM K3Fe(CN)6 
5 mM K4Fe(CN)6 
2 mM MgCl2 
0.02% (v/v) NP-40 
0.01% (w/v) Natrium Deoxycholate 
500 µg/ml X-Gal 
1x PBS 
LacZ-buffer 2 mM MgCl2 
0.02% (v/v) NP-40 
0.01% (w/v) Sodium Deoxycholate 




Running buffer 50% (v/v) Glycerol 
0.02% (w/v) Xylenecyanol 
0.02% (w/v) Bromphenol blue 
0.02% (w/v) SDS 
100 mM EDTA 
MBSTL buffer pH 7,5 0.15 M NaCl 
0.1 M Maleic acid 
2 mM Levamisole 
0.1% Tween-20 
New Fuchsine chromogen 0.6% (v/v) N,N-Dimethyl formamide 
0.05% (w/v) Levamisole 
0.03% (w/v) Naphtol As-Bi Phosphate 
0.02% (w/v) NaN3 
0.01% (w/v) New Fuchsine 
1x TBS pH 8.8 
 (Tris-buffered saline solution) 
Neutralizing buffer 2.55 M Potassium acetate pH 5.5 
Low stingency buffer 0.1% SDS 
2x SSC pH 7.0 
NT-buffer 0.15 M NaCl 
0.1 M Tris/HCl pH 7.5 
NTM-Puffer 0.1 M NaCl 
0.1 M Tris/HCl pH 9.5 
50 mM MgCl2 
NTMLT-buffer 0.1 M NaCl 
0.1 M Tris/HCl pH 9.5 
50 mM MgCl2 
2 mM Levamisole 
0.1% Tween-20 
Paraformaldehyde 4% (w/v) Paraformaldehyde 
1x PBS 
Phosphate buffered saline solution, 10x, pH 7,4 (PBS, stock 
solution) 
1.4 M NaCl 
27 mM KCl 
15 mM KH2PO4 
65 mM Na2HPO4 
Proteinase K-buffer 50 mM Tris/HCl pH 8.0 
5 mM EDTA 
40 µg/ml Proteinase K 
Resuspension buffer 50 mM Tris/HCl pH 8.0 
10 mM EDTA 
100 µg/µl RNase A (Ribonuclease A; Qiagen 
GmbH, Hilden) 
Standard sodium citrate solution (SSC), 20x pH 7.0  0.3 M Sodium citrate 
3 M NaCl 
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STE-buffer  50 mM Tris/HCl pH 8.0 
100 mM NaCl 
1 mM EDTA 
1% (w/v) SDS 
STE-in situ-buffer 10 mM Tris/HCl pH 8.0 
5 mM EDTA pH 8.0 
0.5 M NaCl 
Stop-buffer 10 mM Tris/HCl pH 8 
1 mM EDTA 
Tris-EDTA buffer pH 9,0 (TE) 10 mM Tris 
1 mM EDTA 
Tris-Boric acid-EDTA Solution, 10x (TBE; stock solution) 890 mM Tris/HCl pH 8.0 
 730 mM Borsäure 
 12.5 mM EDTA 
Tris-buffered saline solution, 10x (TBS; stock solution) 0.5 M Tris/HCl pH 7.4 
 1.5 M NaCl 
X-Gal stock solution 40 mg/ml X-Gal 
100% N,N-Dimethylsulfoxide (DMSO) 
4.6 Media 
4.6.1 Media for bacterial culture 
 
Lysogeny broth medium (LB medium;1% (w/v) Bacto-tryptone, 0.5% (w/v) yeast extract, 
1% (w/v) NaCl (pH 7.0) was prepared with double-distilled water, autoclaved and stored at 
4°C. By adding 50 μg/ml ampicillin (Carl Roth GmbH, Karlsruhe, Germany) or 25 μg/ml 
kanamycin (Carl Roth GmbH, Karlsruhe, Germany) was carried out immediately prior to use 
of the medium, the selection on respective resistance-mediating genes. 
4.6.2 Agar plates 
 
LB agar plates were prepared using LB medium with 1.5% (w/v) agar. The solution was 
autoclaved and cooled to 55°C. Appropriate antibiotics were added to the warm LB agar. 
Then, the agar was poured into 10 cm Petri dishes. When solidified, the agar plates were 
stored in sterile plastic bags at 4°C. 
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4.6.3 Media and reagents for cultivation of eukaryotic cell lines 
 
Table 6. List of supplementary materials used for cell culture.  
Supplementary materials Supplier 
Dulbecco's Modified Eagle Medium (DMEM) PAN Biotech GmbH, Aidenbach, Germany 
Fetal Calf Serum (or Fetal Bovine Serum) Gibco, Invitrogen GmbH, Karlsruhe, 
Germany 
Horse serum (heat inactivatied) Gibco, Invitrogen GmbH, Karlsruhe, 
Germany 
Insulin Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Penicillin (10000 U/ml)/Streptomycin (10 mg/ml) PAN Biotech GmbH, Aidenbach, Germany 
RPMI 1640 Medium  PAN Biotech GmbH, Aidenbach, Germany 
Sodium selenite Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Transferrin Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
TrypLE Express Gibco, Invitrogen GmbH, Karlsruhe 
4.7 Biological materials  
4.7.1 Bacterial strains and growth 
 
The transformation and amplification of plasmid DNA was done in chemical-competent host 
strain E. coli DH5  (Invitrogen GmbH, Karlsruhe, Germany). Fifty μl of competent cells 
were thawed on ice. One hundred ng of pure plasmid was added and incubated for 20 min, on 
ice. Cells were heat shocked by putting them at 42°C for 45 sec to allow the plasmid to enter 
the cell. Cells were then placed again on ice for 2 min and then filled with 500 μl SOC 
medium and incubated for 1 h at 37°C with gentle shaking. About 10-250 μl of  
transformed cells were plated on agar plates with appropriate antibiotics. Agar plates were 
incubated overnight in an incubator at 37°C. 
4.7.2 Eukaryotic cell lines 
The media and supplements used to grow eukaryotic cell lines are specified in Table 6. 
Eukaryotic cells were generally grown in Dulbecco's Modified Eagle Medium (DMEM) or 
RPMI 1640 medium supplemented with 10% FBS and 1% antibiotics. All cell lines were 
cultured in an incubator with constant 37°C, 5% CO2 and 95% humidity. Media was 
refreshed every 3 to 4 days. When reaching 80% to 90% confluence, the cells were 
passaged. The cell lines and the respective culture conditions are given in Table 7. 
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Table 7. List of the eukaryotic cell lines, media and supplement used in this study.  
Cell line Media Supplement given 
B16F10 
(murine melanoma cells)  
RPMI 1640  10% FBS 
100 U/ml penicillin/(100 μg/ml)Streptomycin 
GIST-T1 
(human GIST cells)  
RPMI 1640  10% FBS 
100 U/ml Penicillin/(100 μg/ml)Streptomycin 
NIH/3T3 
(murine embryonic fibroblast)  
DMEM  10% FBS 
100 U/ml Penicillin/(100 μg/ml)Streptomycin 
L929 
(murine fibroblast)  
RPMI 1640  10% FBS 
100 U/ml Penicillin/(100 μg/ml)Streptomycin 
ID8-Luciferase (ID8-LUC) 
(murine ovarian carcinoma with infected with 
luciferase reporter construct 
DMEM 4% FBS 
5 µg/ml insulin 
5 µg/ml transferrin 
5 ng/ml sodium selenite 
BMDM  
(murine bone marrow-derived macrophages) 
DMEM Pluznik medium for differentiation: 
10% FBS 
30% L929-CM  
5% horse serum  






4.7.3 Mouse lines 
 
All experiments using animals were performed in compliance with all legal and ethical 
requirements. Ptch
flox/flox 
mice were crossed to LysMcre
+/-





 were backcrossed to Ptch
flox/flox 







 mice have loxP sites in Ptch introns 7 and 9 
83
. LysMcre mice express cre 
recombinase under the control of the endogenous LysM-promoter (see introduction). This cre 
driver targets mouse cells of the myeloid lineage, due to their expression of LysM 
104
. R26R-
LacZ and mice carry a cre-inducible LacZ under the control of the endogenous, 




 mice were on a mixed C57BL/6 x 




 mice were 






 mice. In the 
latter mice all LysM-expressing cells are marked by the permanent expression of LacZ. 
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Table 8. Mouse lines used.  
Mouse line Genetic background Genetic modification 
Ptch
flox
 mixed C57BL/6 x Balb/c or 
C57BL/6 
Floxed exons 8 and 9 of the murine 
Ptch gene; useful for conditional 
Ptch gene deletion 
83
 
ROSA26-R C57BL/6 Integration of the beta-




LysMcre C57BL/6 Targeted insertion of cre cDNA 







 C57BL/6 Rag2 coding region is deleted; 
Lacks mature T and B lymphocytes 




4.8 Synthetic Oligonucleotides 
 
Synthetic DNA oligonucleotides were obtained from Qiagen GmbH, Hilden, Germany. The 
stock concentration of 100 μM was adjusted with DNAse and RNAse-free water. For PCR 
(see section 4.10.3) the working concentration was 10 μM. 
Table 9. Gene-specific DNA-oligonucleotides (primers) for mouse genotyping.  
Genotyping 
Primer Name Primer Sequence (5’-3’ orientation) Application 
mLys1 CTTGGGCTGCCAGAATTTCTC Genotyping of LysMcre mice 
mLys2 TTACAGTCGGCCAGGCTGAC 
Cre8 CCCAGAAATGCCAGATTACG 
Rosa1  AAAGTCGCTCTGAGTTGTTAT Genotyping of Rosa26R-LacZ knock-in mice 
Rosa2 GCGAAGAGTTTGTCCTCAACC 
Rosa3 GGAGCGGGAGAAATGGATATG 






Exon 7-F AGGAAGTATATGCATTGGCAGGAG 
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Table 10. List of primers used for semi-quantitative PCR in this study.  
Semi-Quantitative RT-PCR 
Primer Name Primer Sequence (5’-3’ orientation) Application 
mCD21F.1 CTGTGAGAGTGATTTCCCTCTGGA murine CD21 expression 
analysis 
mCD21R.2 GCAAATAGCCAGGTTCACAACTGTA 
mCD23F.1 ATTTCAAAGGGAACTGCATGCA murine CD23 expression 
analysis 
mCD23R.1 ACTAGTCGCCCTTGCAGGTCA 
mCD35F.1 TTGTAATCAAGGATACCGCCTCATT  murine CD35 expression 
analysis 
mCD35R.1 AGAAATCTCCATTGGGAATGCCT 
Krt 7 F1 GCCTGGAGGTGGAACTGCGGAAC murine Krt7 expression 
analysis 
Krt 7 F2 CAGCTCGAGACACTGCAGCTGGAT 




Table 11. List of primers used for quantitative RT-PCR. 
Quantitative RT-PCR 
Primer Name Primer Sequence (5’-3’ orientation) Application 
mHand2F.1 TGGCCAAGGACGACCAGAA murine Hand2 expression analysis 
mHand2R.1  TTCAAGATCTCATTCAGCTCTTTCTTC 
mFoxf1F.1 AACAGCCTCTGTCCCCTTGC murine FoxF1 expression analysis 
mFoxf1R.1 CGAGGGATGCCTTGCAGTTCT 
mPTC10 TACAGTCCGGGACAGCATACC murine Ptch expression analysis 
mPTC11R GTACCCATGGCCAACTTCGGCTTT 
mGli1-tq-f 





murine Gli2 expression analysis 
Gli2-RT-PCR-R GTGTCTTCAGGTTCTCCAGGC 
Gli3F2 GAAGGAACAACCCTAGTCAAGGAGGA murine Gli3 expression analysis 




Primer Name Primer Sequence (5’-3’ orientation) Application 
Gli3-sybrgree R CCAGCGGCACACGAACTCCTTCT 
mPdgfa F 
GCAAGACCAGGACGGTCATTTAC 










murine Pdgfc expression analysis 
mPdgfc R 
CTCTTCCCGTATGGACACTGAG 




human GLI2 expression analysis 
hGLI2 R 
CGTTAGCCGAATGTCAGCCGTGAAG 
PTCH F TGGGATTAAAAGCAGCGAAC 
human PTCH expression analysis 
PTCH R TCTCCAATCTTCTGGCGAGT 
HAND2 F 
CCTTTGAGGCATCTGCTCC 
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Table 12 List of primers used for quantification of recombination efficiency 
108
 . 
Probe based qRT-PCR 






mPTCdelNx_f TTCATTGAACCTTGGGGAACATT intron 7-8 







(in combination with primers mPTCNx_f 








(in combination with primers 
mPTCdelNx_f mPTCNx_r; see above) 
intron 7-8 
Pelo-F1 CGGTCTGAGTGCTGGTAGGGA 3’ UTR quantification of Pelota 
Pelo-R TCTGCACCTTAGCGTGAAGCC 3’ UTR 
Pelo-Sonde2 FAM
8 
~ GAG CGA GCA AAG CCA 






For western blotting see 4.12.  
 
Table 13. List of antibodies used for western blot and the appropriate dilutions. 
Primary antibodies for Western Blot Dilution *** 
pAb rabbit anti- p-cKit (Tyr 719) 
Cell Signaling, 3319 
1:1000 
pAb rabbit anti- p-Pdgfrα (Tyr 754) 
Santa Cruz Biotechnologies, SC12911 
1:500 
pAb rabbit anti- Pdgfrα (C-20) 
Santa Cruz Biotechnologies, SC 338 
1:500 
mAb mouse anti-β actin (C4) 
Santa Cruz Biotechnologies, SC 47778 
1:5000 
mAb rabbit anti- Actin 
Cell signaling 4970S 
1:5000 
mAb mouse anti p-p44/42 (Thr202/Tyr204) 
Cell Signaling, 9106 
1:1000 
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pAb rabbit anti p44/42 
Cell Signaling, 9102 
1:1000 
mAb mouse anti p-c-JUN (KM-1) 
Santa Cruz Biotechnologies, SC-822 
1:200 
mAb rabbit anti c-JUN (60A8) 
Cell Signaling, 9165 
1:500 
secondary antibodies for Western Blot dilution 
pAb mouse anti- rabbit/HRP** 
Sigma AO545 
1:5000 




*:antibody binding was visualized using DAB+ (En vision+ system-HRP, Dako) or 
aminoethylcarbazol as chromogen; **: signals were visualized using the ECL plus detection system 
(GE Healthcare); ***: diluted 0.02% casein in TBS. 
 
Table 14. Primary and secondary antibodies and the antigen retrieval methods used for 
immunohistochemistry. 
primary antibodies for IHC dilution (diluting buffer) antigen retrieval 
pAb rabbit anti-Pdgfrα (C-20) 
Santa Cruz Biotechnologies, SC 338 
1:1000 (TBS) boric acid pH 5.2; 30 
min, 60°C 
mAb rabbit anti- Pdgfrβ (C82A3) 
Cell Signaling 4564 
1:1000 (TBS) citric acid pH 6; heat 
mediated 
pAb rabbit anti- Desmin 
Dianova 13732 
1:1000 (TBS) citric acid pH 6; heat 
mediated 
mAb rat anti- cKit 
Cedarlane CL8936AP 
1:200 (TBS) none 
mAb rat anti-F4/80 
 Serotec MCA497GA; Clone CI:A3-1 
1:100 (0.02% casein in TBS) none  
mAb mouse anti-Ki-67 
BD Pharmingen 
1:50 (TBS) citric acid pH 6; heat 
mediated 
mAb mouse anti-SMA 
Beckman Coulter PN IM1144 clone 
1A4 
1:50 (TBS) none  
mAb rat anti-MHC II (purified anti-
mouse I-A/I-E) BioLegend, #107602 
1: 100 (0.02% casein in TBS) boric acid pH 5.2; 30 
min, 60°C 
pAb rat anti-CD3  
Serotec; Clone CD3-12, MCA1477 
1: 100 (TBS) citric acid pH 6; heat 
mediated 
secondary antibodies for IHC dilution 
En vision+ anti- rabbit/mouse/HRP* 
Dako K5007 
undiluted 
rabbit anti rat/biotinylated 
Dako E0468 and 
Streptavidin/HRP* 
Dako P0397 
1:100 (0.02% casein in TBS) 
 
1:1000 (TBS) 
primary antibodies for 
immunoflourescence 
dilution 
mAb rat anti- cKit 
Cedarlane CL8936AP 
1:200 (TBS) 
mAb rabbit anti- PDGFRα 
Cell signaling 3174  
1:100 (TBS) 
pAb goat anti- GFP 
Rockland 600-101-215  
1:400 (TBS) 
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secondary antibodies for 
immunoflourescence 
dilution 
Rhodamin red conj. anti- rat 
Jackson Laboratories 712-295-153 
1:200 (TBS) 
488 (green) anti- rat 
Invitrogen A-21208 
1:1000 (TBS) 
488 (green) anti- rabbit 
Invitrogen A-21206 
1:1000 (TBS) 




Table 15. Primary antibodies and used for flow cytometric analysis.  
primary antibodies for 
immunoflourescence 
dilution* 
mAb rabbit anti-B220 PE-Cy7  
BD Bioscience 
1:50 
mAb rat anti-CD19 FITC  
BD Bioscience 
1:50 
mAb rat anti-CD3-Cy5  
BD Bioscience 
1:50 
mAb rat anti-TCRβ-FITC 
BD Bioscience 
1:50 
mAb rat anti-CD11b-FITC 
BD Bioscience 
1:50 
mAb rat -Gr1- PE 
BD Bioscience 
1:50 
mAb rat -IL4Rα 
BD Bioscience 
1:50 
* All antibodies were diluted in PBS. 
4.10 Molecular biology methods 
4.10.1  Nucleic acid isolation 
4.10.1.1  Genomic DNA isolation  
 
Genomic DNA (gDNA) was isolated from tissue which was incubated overnight at 55°C in 
400 μl of STE buffer containing 0.5 mg/ml Proteinase K. Undigested tissue was separated by 
centrifugation for 10 min at 13000 rpm. Nucleic acid in the supernatant was precipitated in 
99% ethanol and pelleted by centrifugation (25 min, 13000 rpm). The pellet was washed 
with 70% ethanol, dried and diluted in 125 μl ddH20 for 10 min at 42°C (with shaking). 
4.10.1.2  Total RNA isolation 
 
RNA was extracted from tissue and cell samples using TRIzol reagent (Invitrogen), 
following the manufacturer's instructions. Briefly, cells were rinsed with PBS and detached 
in 1 ml TRIzol by pipetting. To avoid RNA degradation the following steps were performed 
on ice, unless stated otherwise. Samples were vortexed for 2 min and then incubated for 5 
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min at room temperature (RT). Subsequently, 200 µl chloroform were added followed by 
vortexing for 15 sec and an incubation step for 3 min at RT. Afterwards, the mixture was 
centrifuged for 10 min at 6000 g and 4°C. The upper phase was transferred into a new 1.5 ml 
E-cup containing 1 ml isopropyl alcohol, inverted and precipitated overnight at -20°C. 
Subsequently, the mixture was centrifuged for 30 min at 10000 g and 4°C. The supernatant 
was discarded and the remaining pellet was washed with 1 ml 70% ethanol (-20°C) by 
centrifugation for 10 min at 10000 g and 4°C. Afterwards, supernatant was removed and the 
pellet was air-dried at RT. Subsequently, pellet was dissolved in 20 µl RNase-free H2O for 
5-10 min at 56°C.  
The DNA and RNA concentration were measured using a photometer (see quantification 
method below).  
4.10.2 Photometric quantification of nucleic acids  
 
One µl of DNA or RNA sample was diluted (100x) in RNAse- and DNAse-free water. The 
concentration of nucleic acids was measured using a photometer at a wavelength of 260 nm 
to quantify the DNA/RNA and at a wavelength of 280 nm to determine the purity of the 
sample. DNA or RNA concentrations can be estimated by measuring the optical density at 
260 nm (OD260), using the relationship that an OD260 of 1.0 equates 50 µg/ml or 40 µg/ml 
pure DNA or RNA, respectively. The concentration thus can be calculated according to the 
following formula: concentration (µg/ml) = OD260 × dilution factor × 50 (for DNA) or 40 
µg/ml (for RNA). The purity of the sample was assessed by OD reading at 280 nm (OD280) 
for the amount of protein in the sample. Pure preparations of DNA and RNA have 
OD260/OD280 values of 1.8 to 2.0, respectively. 
4.10.3 Polymerase chain reaction (PCR) 
4.10.3.1 Reverse Transciption (cDNA synthesis) 
 
Two μg of RNA were reverse transcribed in a final volume of 20 µl. 250 ng hexamers were 
incubated with RNA for 10 min at 70°C. Next, 1st strand buffer (Invitrogen), 10 mM DTT 
(Invitrogen) and 0.5 mM dNTPs were added and incubated at 25°C for 10 min and then at 
42°C for 2 min. Subsequently, 50 or 100 U SuperScript II Reverse Transcriptase (Invitrogen) 
was added and the mixture was incubated for 1 h at 42°C. The reaction was stopped at 70°C 
for 10 min. Under the assumption that the reverse transcription was 50% efficient, the 
amount of cDNA was estimated 50 ng/μl cDNA  
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4.10.3.2 PCR for gDNA and cDNA semi-quantification 
 
The amplification of DNA was done in reaction volumes of 10 or 20 μl per assay and was 











The primers used for genotyping or semi-quantitative PCR are listed in Table 9 and Table 10, 
respectively. The PCR conditions varied depending on the assay but always included: 1) 
initiation step of 5 to 10 min at 95°C; 2) denaturation step of 30 to 60 sec at 95°C; 3) 
annealing step of 30 sec to 2 min at 55° to 68°C, depending on the DNA oligonucleotide 4) 
elongation step at of 1 to 2 min at 68° or 72°C. Steps 2) to 4) were repeated between 25 to 35 
cycles. The reaction was terminated by a final elongation step for 10 min at 72°C. The 
reaction was analyzed by agarose gel electrophoresis. 
4.10.3.3 Quantitative RT-PCR  
 
Gene expression was analyzed by SYBR-green-based qRT-PCR assays. All primer pairs 
used for amplification were intron-spanning and they are shown in (Table 12). The reaction 
contained 2.5 ng template-cDNA, 0.4 μM sequence-specific forward-DNA-oligonucleotides, 
0 .4 μM sequence-specific reverse-DNA-oligonucleotides and 1x SYBR Green in a total of a 
10 μl reaction mixture. For quantification of the expression of murine genes data were 
calculated using the standard curve method. Each gene that was measured had a 
corresponding standard curve with cDNA created as a template. To prepare the standard 
curve for each gene, 1:5 serial dilutions of the standard sample (previously known to express 
the gene of interest) were prepared and amplified. Based on the determined values of the 
standard curve, a linear trendline was generated by plotting the logarithm of the quantity 
against the Ct-value for each dilution. Thus, the linear trendline follows the equation y = mx 
10 - 100 ng DNA template 
0.5 µM sequence-specific forward DNA oligonucleotide (forward primer) 
0.5 µM sequence-specific reverse DNA oligonucleotide (reverse primer) 
0.2 mM dNTP-Mix 
1% (v/v) N.N.-Dimethylsulfoxide (DMSO) 
10% (v/v) Cresol 
1x Polymerase-buffer 
0.1 U Polymerase 
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+ b. With this equation the quantity of each gene was determined. The expression of the 
specific genes was normalized to the expression of 18S rRNA in the respective cDNA 
sample. The results were analyzed using SDS 2.2.1 (Applied Biosystems) and Microsoft 
EXCEL (Microsoft Co).  
4.10.3.4 Recombination Assay 
 
The degree of recombination at the targeted Ptch locus in myeloid cells was estimated by 
quantitative real-time PCR in gDNA using primers and TaqMan probes as described 
previously 
108
. All primers and probes used are listed in Table 12. The primer combination 
mPTCdelNx_f/mPTCNx_r amplifies a fragment after cre-mediated excision of the floxed 
locus i.e. of the deleted Ptch
del
 allele. This fragment was detected using a 6-
carboxylfluoreceine-labeled probe (mPTCdelNx_S1). The primers mPTCNx_f/mPTCNx_r 
amplify a fragment of the Ptch
flox
 locus, which was detected with a Yakima Yellow-labeled 
probe (mPTCNx_S2). A pelota gene-specific quantitative PCR-assay (primer combination 
Pelo-F1/Pelo-R, probe Pelo-Sonde2) was used for data normalization. The standard curve 
method for relative quantification was used for data analysis. The deletion efficiency was 
calculated as the ratio of the values for the deleted allele to the total value from the floxed 
allele plus the deleted allele and is denoted in percent. Each sample was measured in 
triplicates. 
4.10.4 Agarose gel electrophoresis 
 
To separate DNA fragments, gel electrophoresis was done. Depending on the size of the 
expected DNA fragments, gels in TBE buffer containing 1 to 2% (w/v) agarose and 0.2 
μg/ml ethidium bromide were used. The electrophoresis chamber was filled with TBE buffer 
and the gels were loaded with DNA samples. In parallel a DNA ladder was loaded. The gels 
were run at a constant voltage of 30 to 100. A UV transilluminator (Intas, Göttingen, 
Germany) was used for documentation. 
4.11 Cell biology methods 
4.11.1 Isolation of bone marrow cells and preparation of murine bone marrow-derived 
macrophages (BMDM) 
 
Isolation of BM and BMDM was performed as previously described 
109
, with minor 
modifications. To isolate BM, femurs were obtained from 8-13 week old mice. The femurs 
were dissected using scissors and were removed by cutting the tibia below the knee joints 
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and the pelvic bone close to the hip joint. Muscles connected to the bone were removed 
using clean gauze. The femurs were placed into a petri dish on ice until use. Under a tissue 
culture hood, the bones were sprayed with 70% ethanol and then both epiphyses were 
removed using sterile scissors and forceps.  
 
To collect BM cells, BM were flushed with 2.5 ml sterile PBS using a syringe. Cells were 
then resuspended in 10 ml PBS. Cells were pelleted by centrifugation at 1200 rpm for 10 
min at 4˚C. Cells were resuspended in 5 ml PBS and counted. 
 
In order to grow BMDM, the bones were flushed with 2.5 ml of Pluznik medium using a 
syringe. In order to allow the settling of adherent cells such as fibroblast, cells were grown 
overnight in a total of 10 ml Pluznik medium. The next day, non-adherent cells in the 
supernatant were centrifuged at 1200 rpm for 10 min at RT. The cells were resuspended in 
40 ml of Pluznik medium and divided into 4 non-coated 10 cm culture petri dishes. Four 
days later, the medium was replaced by 10 ml/plate of fresh Pluznik medium. The cells were 
incubated for an additional 3 days. For further use, cells were washed with sterile PBS, 
enzymatically detached (using TrypLE express) and resuspended in BMDM culture media. 
Cells were counted and seeded at 8000 - 15000 cells/well in a 96-well culture plate for cell 
viability and proliferation assays (see below). BMDM were cultivated for at least 12 hours 
before further manipulation. 
4.11.2 Isolation of splenocytes 
 
Spleen was removed and pressed through a fine-mesh cell strainer (40 μm pore size) in a 
petridish containing 10 ml PBS. Single cell suspension was made by repeated suction with a 
syringe through a fine needle (gauge 22). The splenocytes were centrifuged at 300 g for 5 
min at 4°C and resuspended in 5 ml of PBS. Cells were counted using the Neubauer chamber. 
4.11.3 Isolation of CD11b+ and CD11c+ cells 
 
Whole blood cells or 10
7
 splenocytes (see 4.11.2) or were pelleted by centrifugation at 300g 
for 10 min. The pellet was resuspended in 90 μl of buffer (PBS pH 7.4 with 0.5% bovine 
serum albumin (BSA) and 2 mM EDTA). Then 10 μl of CD11b/CD11c MicroBeads 
(Miltenyi Biotec) was added to the cells and incubated for 15 min at 4°C. The cells were 
pelleted by adding 1 ml of buffer and centrifuged at 300 g for 10 min. The supernatant was 
removed and the cells were resuspended in 500 μl of buffer. The magnetic separation column 
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was prepared by placing the column in the magnetic field separator and rinsing the column 
with 500 μl of buffer. After rinsing, the resuspended cells were loaded into the prepared 





 cells remained attached to the column. The column was washed 




 fraction, the column was 





were immediately flushed out by firmly applying the plunger after adding 1 ml buffer on the 
column. 




 whole blood cells were resuspended in 1 ml PBS in a 2 ml tube. Then 25 μl of 
resuspended magnetic beads (Dynabeads, Invitrogen) was added to the cells and incubated 
for 20 min at 4°C. Then the tube was placed on a magnet for 2 min before carefully removing 
the supernatant. The cells were washed by removing the tube from the magnet and adding 1 
ml of isolation buffer (PBS pH 7.4 with 0.1% BSA and 2 mM EDTA). The cells were 
vortexed shortly (2–3 sec) and the tube was placed again in the magnet for 2 min. While the 
tube was still in the magnet, the supernatant was carefully removed and discarded. The 
washing step was repeated once more before using the cells for isolation of RNA. 
4.11.5 Analysis of blood and bone-marrow-derived cells 
4.11.5.1 Differential blood count and smears 
 
Whole blood isolated from mice was transferred directly into EDTA tubes and mixed well to 
prevent coagulation. The blood samples were stored until analysis at 4°C (maximally 6 h). 
The differential blood cell counting of non-coagulated whole blood was done on an AcT5 
hematology analyzer. The blood smears were stained with Hemacolor before counting. 
4.11.5.2 Cytospin preparation from bone marrow 
 
BM cells were isolated as described in 4.11.1. Two hundred thousand cells of each sample 
were centrifuged (Cytospin 2) at 1500 rpm for 3 min onto microscope slides. Upon 
Pappenheim staining, the cells were analyzed by a train hematopathologist.  
  
Materials and Methods 
38 
 
4.11.6 Stimulation of BMDM with LPS or BLP 
 
After isolation and differentiation of BMDM, cells were counted and seeded at 15000 
cells/well in a 96-well culture plate. Cells were allowed to adhere to the plate overnight. The 
following day, supernatants were removed and medium containing 100 ng/ml LPS or BLP 
(stock concentration is 1mg/ml in water) was added for 6 to 72 hr.  
4.11.7 Cell viability and cell proliferation assay 
 
To test the viability of BMDM, WST-1 reagent was used. Briefly, 15000 cells were seeded in 
96-wells. Four hours before the end of treatment, supernatants were removed and cells were 
incubated with 10 μl of WST-1 reagent in 100 μl fresh media at 37
◦
C for 3 to 4 h. During this 
time the tetrazolium salt WST-1 was cleaved to a soluble formazan dye. This bioreduction is 
largely dependent on the glycolytic production of NAD(P)H in viable cells. Therefore, the 
amount of formazan dye (quantitated by spectrophotometer at a wavelength of 450 nm) is 
proportional to living cells.  
The proliferation of BMDM was analyzed using the BrdU Cell proliferation kit (Roche). The 
assay was done according to the manufacturer's instruction. Briefly, 8000 cells were seeded 
in 96-well plates. Twenty two hours prior to the end of treatment, BrdU reagent was added. 
Cells were then fixed. The cell membrane was denatured and probed with anti-BrdU-POD for 
1 h. After thorough washing, BrdU incorporation was determined by adding peroxidase 
substrate and measurement of luminescence using a luminometer. The measured 
luminescence is proportional to the proliferation of cells. 
4.11.8 Flow cytometric analysis 
 
For flow cytometric analysis, 1x10
6
 splenocytes (see 4.11.2), cells were put in a brown 1.5 ml 
reaction tubes and incubated on ice for 20 min with the appropriate antibodies (diluted 1:50 
in PBS; see also Table 15) in a 50 μl total volume. Then the cells were washed by adding 300 
μl PBS and centrifuged for 5 min at 300 g and 4°C. The cell pellet was resuspended in 300 μl 
PBS and stored (maximally 1 hr) on ice until flow cytometric measurement. 
 
For flow cytometric analysis of whole blood cells derived from the retro-orbital venous 
plexus or from tumor ascites, 49 μl of sample was incubated with 1 μl antibodies for 20 min 
on ice. This was followed by lysis of erythrocytes by adding 1ml of ready-to-use lysis buffer 
(BD Pharmingen) for 10 min at 4°C. The cells were then centrifuged for 5 min at 300 g and 
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4°C to remove the lysis buffer and then washed twice with 1 ml PBS by centrifugation for 5 
min at 300 g and 4°C. The cell pellet was resuspended in 300 μl PBS and stored (maximally 
1 hr) on ice until flow cytometric measurement. 
 
BD LSR II flow cytometer was used for data collection and analysis was performed using the 
BD FACSDiva ™ software. 
4.11.9 Enzyme-linked immunosorbent assay (ELISA) 
 
Commercially available ELISA kits were used according to the manufacturer's instruction. In 
short, the supernatants of stimulated BMDM (see 4.11.2) were collected at different time 
points (6, 12 and 24 h after treatment) and centrifuged at 13000 rpm for 10 min to pellet the 
cellular debris. The levels of IL-6, IL-10 and MCP-1, MIP-1α, RANTES and KC were 
measured using the DuoSet ELISA Kit (R & D systems). TNFα and IL-12p40 were 
quantified using a kit from BioLegend and EBioscience, respectively.  
4.11.10 Cellular transformation assay 
 
To test for cooperation of HH/GLI and PDGFRA signaling in oncogenic transformation, 
1x10
4
 human non-tumorigenic HaCaT keratinocytes expressing GLI1 under the control of a 
tetracycline inducible promotor 
110
 were seeded as single cells in 12-well plates in 0.4% 
select agar on top of 0.5% bottom select agar (Invitrogen). Cells were either treated with 50 
ng/ml doxycycline (Dox) (Sigma) to induce GLI1 expression, 50 ng/ml recombinant PDGF-
BB (R&D Systems) or with a combination of Dox/PDGF-BB. To assay possible cooperation 
of HH/GLI with KIT signaling, the same GLI1-expressing HaCaT cells were stably 
transduced with the constitutively active D816V KIT mutant (GNNK+ splice form) 
111
. 
Empty-vector transfections served as controls. 3D transformation assays were incubated for 
4 weeks at 37°C with 5% CO2. Anchorage independent clonogenic growth was documented 
with a Cell^D Image capture system and quantified by automated colony counting using 





4.12 Protein chemistry and immunohistochemistry methods 
4.12.1  Protein isolation and quantification 
 
                                                 
*
This method was done in collaboration with Prof. Fritz Aberger, University of Salzburg, Austria. 
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Tissues samples were collected, washed thoroughly with sterile PBS and homogenized in 
RIPA buffer. The protein concentration was measured using the Pierce BCA Protein Assay 
Kit according to manufacturer’s instructions. Bovine serum albumin was used as the 
standard. 
4.12.2 Western blot 
 
For western blot analyses, 50 µg of total tissue protein lysates were denatured with sample 
buffer for 5 min at 96°C. Proteins were loaded on NuPAGE Novex Midi Gels in 1x running 
buffer (NuPAGE MES SDS buffer) and electrophoresed for 1.5 to 2 h at 160 mA. Four µl of 
pre-stained protein standard (SeeBlue Plus2) was loaded in parallel to estimate the molecular 
weight of the proteins. Proteins were transferred to a nitrocellulose membrane (GE 
Healthcare) using a semi-dry blotting device at 120 mA for 90 min. After blocking with 
0.2% casein/PBST for 1.5 h at RT, membranes were probed with the appropriate primary 
antibodies (Table 13) at 4°C overnight. Subsequently, the membrane was washed 3x 10 min 
in PBS with 0.1% Tween 20 and then incubated in HRP-conjugated secondary antibody for 
1 h at RT. After thorough washing in PBS with 0.1% Tween-20, 1.5 ml the detection reagent 
(Amersham ECL Plus Western Blotting Detection Reagents) was pipetted onto the 
membrane and incubated for 3 min at RT. For visualization, a Hyperfilm ECL was placed on 
the membrane and developed in a developing machine (Curix 60, Agfa).  
4.12.3 Hematoxylin-Eosin (HE) Staining 
 
For HE staining, paraformaldehye-preserved tissue was embedded in paraffin and cut to 4-5 
μm sections and mounted on glass slides. Sections were initially deparaffinized with xylene 
for 20 min and subsequently rehydrated using descending ethanol solutions (100% to 70% 
ethanol). After extensive washing with ddH2O, slides were placed in hematoxylin solution 
for 15 min. The color development was done with running lukewarm tap water for at least 5 
min. Samples were then quickly dipped in 1% eosin solution (with freshly added 0.5% v/v 
glacial acetic acid). After staining, slides were again washed with ddH2O and dehydrated 
using ascending ethanol solutions (70% to 100% ethanol). Slides were placed again in 
xylene before mounting in Pertex. In order to solidify the mounting medium, the slides were 
placed in an oven at 55°C for at least 15 min.  
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4.12.4 Electron microscopy 
 
After perfusion of the tumor-bearing mice (see 4.13.3), tumor samples were taken and fixed 
in 2.5% gluteradehyde. Samples were then postfixed with 1% osmium tetroxide (Serva, 
Heidelberg, Germany) and embedded in araldite (Serva). Ultrathin sections were cut using 
an ultramicrotome and contrasted with lead citrate (Serva) and uranyl acetate (Serva). 
Investigations were performed on a Zeiss EM10 transmission electron microscope (Zeiss, 
Oberkochen, Germany) equipped with a MegaView III imaging system (Olympus Soft 
Imaging Systems GmbH, Münster, Germany).
†
 
4.12.5  In situ hybridization 
 
For in situ hybridization, all solutions were treated with 300 μl/L DEPC and autoclaved 
before use. Formalin-fixed tissue samples were embedded in paraffin and sectioned to 4-5 
μm thickness. The probe sequences for mouse
 
Gli1 are reported in Wijgerde M et al 
113
. The 
Ptch specific probes were a 477 bp fragment spanning exons 2 to 6, and a 250 bp fragment 
spanning exons 8 and 9 of the Ptch gene 
92
. In situ hybridization was performed as 
previously described 
114
. Briefly, sections were dried at 65°C for 30 min and deparaffinized 
with xylene. Sections were rehydrated through decreasing ethanol solutions (100% to 30%). 
After washing with PBS and saline, the sections were post-fixed in 4% PFA/PBS for 20 min 
on ice. After two additional washing steps in PBS, the tissue was permeabilized with 40 
µg/ml proteinase K for 7.5 min and washed again in PBS. Subsequently, the sections were 
refixed in 4% PFA/PBS for 5 min on ice and transferred to 0.1 M triethanolamine, pH 8.0. 
After adding 0.25% (v/v) acetic anhydride, sections were incubated in the solution for 10 
min then washed with PBS and 0.83% NaCl. Samples were dehydrated through increasing 
ethanol solutions (30% to 100%) and air dried. Sense and antisense (as negative control) 
probes were diluted in hybridization buffer and denatured for 2 min at 80°C, chilled on ice 
and 60 µl of the solution was pipetted on the tissue sections. The sections were covered with 
coverslips and incubated overnight at 59°C in a chamber with paper towels soaked in 50% 
formamide/5x SSC to prevent dehydration of the sections. The next day coverslips were 
removed with 5x SSC and slides were washed in 5x SSC at 55°C. This was followed by a 
high stringency wash in 50% formamide/2x SSC for 20 min at 63°C. Afterwards, the 
sections were washed once at RT and thrice at 37°C in STE-in situ-buffer for 10 min each. 
                                                 
†
 These experiments were done in collaboration with Prof. Dr. Walter Schultz-Schaeffer, Department of 
Neuropathology, University of Goettingen 
Materials and Methods 
42 
 
Then the sections were incubated with 10 ng/ml RNase A in STE-in situ-buffer for 30 min at 
37°C and then washed again for 15 min in STE-in situ-buffer at 37°C. Once again the slides 
were washed with 50% formamide/2x SSC for 20 min at 63°C then transferred to 2x SSC for 
15 min and placed in NT-buffer for 10 min. Subsequently, sections were washed thrice for 5 
min with MBSTL-buffer and incubated for 1 h with 0.2% I-block/PBS to block unspecific 
binding sites. Afterwards, anti-Dig/AP (1:1000 in 0.02% I-block/MBSTL-buffer) was 
pipetted onto the sections and incubated overnight at 4°C. On the following day, slides were 
washed six times for 15 min with MBSTL-buffer and thrice for 5 min with NTMLT-buffer. 
Finally, BM-Purple was pipetted onto the sections and the staining reaction was performed 
in the dark. To stop the staining reaction, slides were transferred to stop-buffer, washed 2 x 5 
min PBS and fixed 1 to 2 h in 4% PFA/0.2% glutaraldehyde in PBS. Finally, the sections 
were washed with PBS and mounted using Glycer gel. 
4.12.6 LacZ staining 
 
LacZ activity was analyzed according to standard procedures. Briefly, tissues were fixed for 
2 h in 4% paraformaldehyde/PBS, washed and soaked in 25% sucrose/PBS overnight. For 
cryosectioning, tissues were embedded in OCT compound and cut to 5 μm sections at -20 to 
-22˚C. Next, cryosections or whole tissue blocks were fixed with 0.2% glutaraldehyde in 
PBS and washed in LacZ buffer. Both, cryosections and tissue blocks were stained in LacZ-
staining solution overnight at 30˚C. Reaction was stopped by washing the tissues or 
cryosections twice with PBS. 
4.12.7 Immunohistochemistry (IHC) 
 
LacZ-stained cryosections were further used for immunohistochemical analysis of Kit. The 
sections were washed in PBS, post-fixed in acetone for 10 min and air-dried before IHC 
staining was performed as described below. 
LacZ-stained whole tissue samples were used for Pdgfrα IHC. For this purpose, the tissue 
was embedded in paraffin and cut to 4 to 5 μm sections. IHC was performed using anti-
Pdgfrα antibody as described below. 
For immunohistochemical staining, sections were deparaffinized and rehydrated. Whenever 
necessary, permeabilization treatment was done (see Table 14). Sections were blocked with 
3% H2O2 to inhibit endogenous peroxidase and blocked once again with 0.2% casein to 
block non-specific antibody binding. Thereafter, the sections were incubated with a primary 
and an appropriate secondary antibody (see Table 14) in a humid chamber. Antibody binding 
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was visualized using DAB+ (Envision+ system-HRP, Dako) or aminoethylcarbazol as 
chromogen. To stop the reaction, slides were rinsed with distilled water. 
All LacZ/IHC doublestained sections were counterstained with hematoxylin. 
For the quantification of Ki-67, pictures were taken from Ki-67-stained sections using the 
CellF software. 1000 cells were counted and analyzed for Ki-67 positivity. Ki-67 positive 
cells are given in percent. 
4.12.8 Assessment of skin thickness and nevi area 
 
The skin thickness was assessed as previously described 
115
, with minor modifications. 
Briefly, 6 representative areas of HE stained (see 4.12.3) skin samples of each animal were 
examined. In each area, the thickness of the epidermis from the basal layer to the stratum 
granulosum and stratum spinosum but excluding the stratum corneum was measured using 
Cell F software. If the mice developed skin papillomas, only the thickness of the papilloma-
free epidermis was measured. Data is presented as boxplot with mean ±SE. 
 
To measure the nevi area, 6 HE stained (see 4.12.3 ) skin samples per mouse were analyzed. 
Whole skin samples were examined for the tumor cells, which presented as black cells. The 
whole area including the stroma between the tumor cells were measured using Cell F 
software. The sum of nevi area per skin sample was normalized to the total skin area that was 
measured. Two independent investigators performed the measurement. 
4.13 Animal Experiments 
 
All experiments using animals were performed in compliance with all relevant legal and 
ethical requirements. 
4.13.1 Breeding of mice 
 
The mouse strains used in this thesis were bred and maintained in the animal facility of the 
Institute of Human Genetics, University of Göttingen. Animals were housed in Makrolon 
cages type II and III, with a twelve-hour light-dark cycle (light period: 6.a.m.-6 p.m.), a 
temperature of 20 ± 2 ° C and a relative humidity of 50 ± 10%. Rodent pellets (complete diet 
for mice breeding) and tap water were given ad libitum to the animals. 
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4.13.2 Tail biopsy and genotyping of mice 
 
To identify the mice, tail biopsies (cut approx. 0.2 cm from the tip of the tail) were taken and 
ear markings were done in four week old mice. 
The genotyping of mice was done by PCR on gDNA from tail biopsies. The oligonucleotides 
and PCR conditions are given in Table 9. 
4.13.3 Perfusion of mice 
 
Mice were injected with a lethal dose of a mixture of Ketanest S (4 mg) and Rompun (0.9 
mg). The chest of the animal was opened and the heart was exposed. The right atrium was cut 
open for bleeding. The left ventricle was punctured. Then the animal was infused with Ringer 
lactate solution for 10 min. Afterwards, the animal was infused with 2.5% glutaraldehyde for 
additional 10 min or until the animal was completely fixed. The organs or tissues were 
removed and put in 4% paraformaldehyde or 2.5% glutaraldehyde (for electron microscopy 
samples) and stored at 4°C until analysis.  
4.13.4 Isolation of tumors 
 
Mice were closely monitored for the development of tumors twice a week. Furthermore, the 
animals were examined for other symptoms such as ataxia, cachexia and lethargy. When 
mice developed a distended abdomen they were killed by cervical dislocation. After killing 
the mice were fixed on the preparation table and disinfected with 70% ethanol. Every mouse 
was thoroughly examined for tumors or other abnormalities. All tumors were carefully 
removed and rinsed with PBS. In case of cystic tumors, the cystic fluid was removed and the 
solid tissue or sac was thoroughly washed with PBS. Normal reference tissue (mostly 
intestine) was also isolated. 






 mice were irradiated with 7 Gy to eliminate the existing BM 






 mice (as 
described in 4.11.1). After counting, 2x10
6
 cells were transplanted by tail vein injection into 
the irradiated mice. Reconstitution of the BM engraftment was analyzed by monitoring 
peripheral blood 6 weeks after transplantation by flow cytometry using anti-TCRß-FITC, 





Materials and Methods 
45 
 
reconstituted with control or Ptch mutant BM cells were observed for 250 days. Flow 
cytometry analysis procedure is described in section 4.11.8. 
4.13.6 Tumor xenografts 
 
Xenograft experiments were performed essentially as described in Schnidar et al.
112
. In brief, 
1x10
6
 Dox inducible GLI1-HaCaT cells transduced with the PDGFRAH650Q mutation 
(PDGFRA
mut
; generous gift from Steffen Koschmieder, Department of Haematology and 
Oncology, Universitäts klinikum Aachen, Germany) or with empty vector control (pBabe-
puro) were injected subcutaneously into the flanks of nude mice. In vivo GLI1 expression 
was induced by Dox added to a final concentration of 2 mg/ml to the drinking water 
containing 2% sucrose. Tumor growth was monitored over a period of 3 weeks and tumor 
volume was calculated as described in Eberl et al. 
116
. Statistical significance was calculated 
with Dunnett´s multiple comparison test. 
‡
 
4.13.7 Imatinib treatment of mice 
 
Imatinib tablets were pulverized and dissolved in PBS. Stock solutions (15 mg/ml) were 




 mice were randomized 
into 4 groups. Two groups were treated orally with 0.1 g/kg imatinib (dissolved in 200 μl 
PBS), as previously described 
117
. The treatment was continued daily for 10 or 12 weeks. 
Vehicle-treated (PBS) mice served as controls. Mice were weighed once a week to monitor 
their conditions. Following the completion of the treatment all mice were sacrificed and 
screened for tumors. 




mice was randomized into 2 groups. The 
first group received imatinib (0.1 g/kg) and the second group served as vehicle treated 
controls. After 10 weeks of daily oral treatment, the treatment was stopped and the animals 
were kept for additional 3 weeks before they were sacrificed and screened for tumors.  
All tumors were embedded in paraffin and examined microscopically via HE stained 
sections. 
4.13.8 Transplantation of syngeneic melanoma cells  
 
Eight to 9 week-old mice were transplanted with B16F10 cells. For this purpose, sub-
confluent B16F10 cells were detached with trypsin solution, counted and resuspended in 
PBS. For the induction of subcutaneous solid tumors, 1×10
4 
cells diluted in 100 μl PBS were 
                                                 
‡
 Xenograft experiments were done in collaboration with Prof. Fritz Aberger, University Salzburg, Austria. 
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. Mice were sacrificed when the tumor reached a size of 2 
cm
3
. For analysis of the metastatic behavior of the cells, 1×10
5 
cells in 100 μl PBS were 
injected into the tail vein. Twenty days post-injection, mice were sacrificed and tumor 
nodules in the lungs were counted.  
4.13.9 Transplantation of syngeneic ovarian carcinoma cells and bioimaging 
 
ID8 cells are transformed late-passage mouse ovarian surface epithelial cells from adult 
C57BL6 mice. Intraperitoneal injection of these cells into syngeneic mice results in tumor 
growth throughout the abdominal cavity and in production of a hemorrhagic ascitic fluid 
119
. 
The ID8-LUC cells express luciferase (introduced by lentiviral infection 
120
) and were kind 
gifts from Dr. Thorsten Hagemann (Queen Mary, University of London). Ten million ID8-
LUC cells were injected i.p. into 8 week-old mice. In order to monitor tumor growth 
bioluminescence images were taken from mice injected i.p. with 150 μg/g body weight D-
luciferin in PBS. Mice were anaesthetized with Isoflouran vapor while images were taken. 
Grayscale images were acquired with low light with an exposure of 0.5 sec. 
Bioluminescence images were acquired in the dark 5 min later using an exposure time of 5 
min in a CCD camera. For analysis of luminescence intensity, the Signal Meta Vue 6.1 
image software (Universal Imaging Corporation) was used. Pseudo-colored overlay images 
of the bioluminescence signal intensities and the mice were generated using VCTEO2D 
Image analyze software.  
Mice injected with ID8-LUC cells also developed an ascites between 13 and 16 weeks post 
injection. At that time animals were euthanized and the ascetic fluid and spleen were 
collected for further flow cytometric and gene expression analyses. 
4.13.10 Two-stage chemical carcinogenesis DMBA/TPA protocol 
 
The dorsal area of mouse skin was shaved 2 days prior to a single application of 200 nM (50 
μg, in 200 μl acetone) of 7,12-dimethylbenzanthracene (DMBA). One week after DMBA 
application, 20 nM 12-O-tetradecanoyl-phorbol-13-acetate (TPA, in 50 μl acetone) was 
applied topically twice a week for 32 weeks. This was done by fixing the neck and tail of the 
mouse by hand and topically applying the chemicals directly on the dorsal skin and waiting 
for 30 sec to allow the solvent to evaporate before releasing the mouse. The area was shaved 
regularly and the number of tumors per mouse was recorded weekly. The weight of the mice 
was also monitored once a week. Animals were sacrificed after the last TPA treatment.  





Table 16. List of softwares. 
Software Distributor 
ABI 3500  Applied Biosystems, Darmstadt, Germany 
Cell F  Olympus Europa GmbH, Hamburg, Germany 
Endnote  Thomson ISI ResearchSoft , California, USA 
FlowJo   Tree Star Inc., Oregon, USA 
Free Hand MX Adobe Systems Incorporated, California, USA  
ImageJ   National Health Institute, Maryland, USA  
Intas GDC   Intas, Göttingen, Germany 
MS Office  Microsoft Co., Redmont, USA  
Photoshop CS3  Adobe Systems Incorporated, California, USA  
SDS 2.1  Applied Biosystems, Darmstadt, Germany 
Statistica 9  StatSoft GmbH, Hamburg , Germany 
4.15 Databases 
 
Table 17. List of database. 
MGI_3.43-mouse genome informatics  http://www.informatics.jax.org/ 
National Center for Biotechnology Information 
(NCBI)/ (NCBI) GEO DataSets 
 http://www.ncbi.nlm.nih.gov/ 
http://www.ncbi.nlm.nih.gov/gds 
European Bioinformatics Institute (EBI)  http://www.ebi.ac.uk/Information/ 
Ensembl  http://www.ensembl.org/index.html 
GeneSapiens http://www.genesapiens.org/ 
4.16 Statistical Analysis  
 
Statistical analyses were performed using the programs MS office Excel and Statistica 
softwares. GSEA analysis on GEO DataSets samples was done by Dr. Annalen Bleckman 







5.1 Generation and phenotype of Ptchflox/floxLysMcre+/- mice 
 
In order to define the role of Ptch in LysM-expressing cells that were expected to be mainly 



















 mice were obtained at the expected 
Mendelian ratio. The floxed Ptch locus is shown in Figure 3A. The presence of the LysMcre 
transgene was detected with the primers MLYS1, MLYS2 and Cre8, which resulted in a 350 
bp and 700 bp fragment derived from the LysM wt and LysMcre locus, respectively (Figure 




 (Figure 3 B and 
C, lane 2) and Ptch
flox/flox
 (Figure 3 C, lane 3) mice is shown Figure 3 B and C. As 
demonstrated in Figure 3A and B, the primer pair mPTCNx_f and mPTCwt_r amplified a 
455 bp fragment derived from the wt Ptch allele, which is detected in Ptch wt and Ptch
flox/+
 
mice. The primer pair mPTCNx_f and mPTCNx_r amplified a smaller 150 bp fragment, 
which was indicative of the Ptch
flox
 allele. The floxed allele was also detected by the primer 
combination Neo-F/p1011R.2, which resulted in a 1735-bp fragment. Moreover, the primer 
pair p910F.4/Neo-R, which resulted in a 843-bp fragment also amplifies the Ptch
flox
 allele 
and will vanish when there is a complete cre mediated recombination of the floxed Ptch 
locus. The occurrence of a 950 bp fragment using the primer pair Exon 7-F and Neo-R is also 
indicative for the cre-mediated recombination event at the floxed Ptch locus. This so-called 
Ptch
del
 allele occurred in the presence of LysMcre
+/-









 mice (Figure 3 C).  
 
These data show that the presence of the LysMcre recombinase results in deletion of the 




 mice. However, due to DNA derived from many 
cells in which the LysMcre was not active, both the floxed and the deleted Ptch locus were 















Figure 3. Scheme and genotyping of the Ptch conditional knock-out mouse model. (A)The figure shows the 
wt Ptch locus and the targeting vector used for homologous recombination. The resulting Ptch
flox
 allele was 
converted into the Ptch
del 
allele in the presence of the cre recombinase. Blue triangles represent loxP-sequences 
in intron 7 and 9. The neomycin resistance cassette (neoR) is flanked by frt sites (grey triangles). The figure was 
adapted from 
83
. The genotyping was done by PCR and performed using mouse tail gDNA (B). Primer 
combinations were as indicated on the left column of the figure. The existence or the absence of the LysMcre 
transgene was identified by PCR with a resulting 700 bp and 350 bp fragment, respectively, using the primer 
combination mLys1, mLys2 and Cre8. (C) The primer locations are indicated in (A) and the primer 
combinations were as indicated on the left column of the figure. Primer pairs mPTCNx_f /mPTCwt_r (455 bp) 





 allele can be detected by primers mPTCNx_f/mPTCNx_r (150 bp), Neo-F/p1011R.2 (1735 bp) 
present in Ptch
flox/+
(lane 2) and Ptch
flox/flox 
mice (lane 3). The primer pairs p910F.4/Neo-R also detects the floxed 
allele (lane 2 and 3) and will disappear in the presence of the cre recombinase. The presence of a 950 bp band 
from primers Exon7-F/neo-R shows the Ptch
del








 mice after 





In addition to genotyping of mice, the recombination efficiency at the Ptch locus was 







 (T) cells. For this purpose, the cells were 
selected using antibody conjugated-magnetic beads (see 4.11.3 and 4.11.4 in the Material and 
Methods section). In addition, the recombination efficiency was analyzed in the whole bone 
marrow and peritoneal macrophages (PM). 
 





 cells, 65% in CD11b
+ 





 mice. These data indicate that a small portion of the T cells and the 














 mice. The data show the mean values (± SEM) of at least 3 different animals. 
Despite being a tumor suppressor gene, the Ptch deletion did not result in tumors of the 
hematopoietic lineage. Thus, the numbers and morphology of cells composing the peripheral 




 mice were normal as revealed by analysis of whole 
blood values (see Table 18), BM and blood  and BM smears (data not shown). Thus, the 




 mice remained 
comparable to the Ptch
flox/flox
 controls. Although the erythrocyte count as well as the 




 mice was slightly lower in 




blood cell indices (MCV, MCH, MCHC) remained normal. The platelet indices (MPV, PDW 
and PCT) also remained comparable to the controls (Table 18).  
 
In addition, blood smears of the mice did not show any indication of hematological defects, 
and BM smear analysis showed no signs of deviations in cell counts and the cells looked 





















Mean SD Mean SD 
WBC (10
3
/μl) 7.987 1.507 8.580 1.899 0.693 
 Neu 1.497 0.497 1.500 0.056 0.991 
 Lym 6.310 0.934 6.903 1.877 0.650 
 Mono 0.123 0.079 0.135 0.066 0.846 
 Eos 0.006 0.004 0.009 0.007 0.502 
 Baso 0.049 0.021 0.046 0.052 0.931 
Ery (10
6
/μl) 11.300 0.265 8.723 1.716 0.062 
Hgb, g/dl 15.433 0.379 12.433 1.834 0.050 
Hct,% 52.433 3.027 43.367 6.200 0.085 
MCV, fl 46.533 2.196 50.100 4.233 0.265 
MCH, pg 13.700 0.361 14.133 1.026 0.528 
MCHC, g/dl 29.467 1.102 28.700 2.364 0.637 
RDW,% 15.067 0.351 18.300 2.252 0.070 
Pl (10
6
/μl) 0.986 0.085 1.042 0.167 0.634 
MPV, fl 3.030 0.327 3.737 0.515 0.115 
PDW 11.333 2.309 16.633 6.413 0.249 
PCT,% 0.300 0.059 0.385 0.037 0.102 
Blood cell numbers were determined by an automated hematological analyzer. WBC: white blood cells; Neu: 
neutrophils; Lym: Lymphocytes; Mono: monocytes; Eos: eosinophils; Baso: basophils; Ery: erythrocytes; Hgb: 
hemoglobin; Hct: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: 
mean corpuscular hemoglobin concentration; RDW: red cell distribution width; Pl: platelet; MPV: mean platelet 
volume; PDW: platelet distribution width; PCT: plateletcrit. P value was calculated using student's t-test (n=3). 
 
Whenever possible, the mice were monitored for at least 398 days after birth. Most 




 mice grew older, many of them developed a 
distended belly. Upon autopsy, tumors located in the gastrointestinal tract were detected.  
                                                 
§
 Blood and BM smear analysis was done by Prof. Claudia Binder in the Dept. of Hematology and Oncology, 




5.2 Ptchflox/floxLysMcre+/- mice develop GlST-like tumors  
5.2.1 Histological characteristics of the tumors of Ptchflox/floxLysMcre+/- mice 
 








 mice developed any kind of 





animals presented with - mostly multiple - tumors arising from the wall of the stomach and/or 
the intestine and/or caecum (Figure 5A and B; Table 19). Larger tumors frequently presented 
as blood-filled cysts protruding into the peritoneal cavity (Figure 5B), whereas smaller, i.e. 
most likely earlier lesions had a solid appearance (Figure 5B and E). The gastrointestinal 




 were initiated from lesions, which were localized 
between either the circular and longitudinal muscle layer or the longitudinal muscle layer and 
the serosa (Figure 5C and D). Although the tumors were located in close vicinity to the 
myenteric plexus, the plexus was frequently intact (Figure 5D). Upon growth (Figure 5E), the 
tumor cells showed a high cellularity, variably spindle-shaped cells, elongated nuclei, and a 
pale eosinophilic cytoplasm (Figure 5F). Histologically, the tumors therefore resembled GIST 
or LMS.  
 
Table 19. Absolute numbers and percentages of symptomatic and symptom-free animals 
used in this study.  






mice with GIST-like 
tumors 





 9 583-670; 
604 
- - 9 
Ptch
flox/flox
 17 96-524; 
324 





 18 398-693; 
640 





 34 116-555; 
206 
28 (82%) 1  5 
1 from birth on  











 mice. (B) Tumors either have a solid (arrow) or cystic appearance (asterisks). The cystic 
appearance is associated with intratumoral bleeding. (C) Shows a precursor lesion (arrow). mus, muscularis (*: 
longitudinal muscle layer; **: circular muscle layer); muc, mucosa; lu, lumen of the intestine. (D) Arrows point 
to the intact myenteric plexus. (E) When precursor lesions become larger (arrows) they adopt a (F) GIST-like 
histology. Scale bars in μm: (B,C and E) 500; (D) 100; (F) 50. 
Electron microscopy of the tumor was done in collaboration with Walter Schulz-Schaeffer, 
pathologist of the department of Neuropathology, University Medical Center Göttingen. 
According to him the tumor cells resembled smooth muscle. This was revealed by the 
occurrence of myofilaments (Figure 6). Moreover, the tumor cells showed an increased 
numbers of mitochondria (marked by red arrows, Figure 6). 
 









mice resemble smooth muscle as shown by myofilaments. The red arrows mark mitochondria in the tumor cell. 




5.2.2 Molecular characteristics of gastrointestinal tumors of Ptchflox/floxLysMcre+/- 
mice 
 
In order to specify the tumors in more detail, the expression of several tumor-specific 
markers was analyzed. In general, the tumors did not overexpress markers of follicular 




 or the mesothelioma-specific 
marker keratin 7 
122
 (Figure 7).  
 
 




mice. A) In comparison to 
normal intestine, tumors do not overexpress CD21, CD23 and CD35, which are markers for follicular dendritic 
tumors. B) Tumors also do not generally overexpress the mesothelioma-specific marker keratin 7 (Krt7). 






In agreement with histology (GIST- or LMS-like), the tumors were positive for the smooth 
muscle marker alpha-smooth muscle actin (αSMA; Figure 8A), which can be expressed by 




. They moderately expressed the LMS-specific marker desmin 
(Figure 8B) and were negative for the GIST-specific marker CD34 (Figure 8C) 
43
. However, 
as revealed by qRT-PCR analysis, the tumors clearly overexpressed the GIST-specific maker 





Figure 8. Tumors express GIST and/or LMS markers. Immunohistochemical analyses showed that tumors 
are positive for the smooth muscle marker αSMA (A) and moderately expressed desmin (B), which can be 
expressed by both GIST and LMS. Although the tumors were negative for the GIST-specific maker CD43 (C; 
see CD34 positive vessels marked by arrow heads), the tumors (Tu, n=3) strongly expressed the GIST-specific 
marker Dog1 (D) in comparison to normal intestine (In; n=3). Normalized qRT-PCR data (± SEM) are shown in 
relation to normal intestine, which was set to 1.  




 mice are rather GIST-
like than LMS-like. 
 
Considering the GIST-like appearance of the tumors, the expression status of Kit and Pdgfrα 
in the tumors was investigated. As revealed by immunofluorescence and 
immunohistochemistry, all tumors were negative for Kit (Figure 9A and D). However, the 










Figure 9. Tumors of Ptch mutant mice express Pdgfrα but not Pdgfrβ or Kit. Immunohistochemical and 




 mice using an anti-Kit (A and D) anti-Pdgfrα 
(B, and D) and anti-Pdgfrβ (C) antibodies. Analyses showed that tumors are negative for Kit but positive for 
Pdgfrα. No Pdgfrα/Kit double-positive cells were detected in the tumors (D, merged right panel). 
Immunohistochemical analysis further showed that the tumor is negative for Pdgfrβ (C).  




 mice were subjected to 
westernblot analyses. The results supported the immunohistochemical stainings and showed 
that the tumors were negative for phospho-Kit and thus, Kit activity. As positive control, a 









 mice strongly expressed 
Pdgfrα (Figure 10B). In addition, Pdgfrα was substantially phosphorylated in tumors when 
compared to normal intestine (Figure 10B). 
 
In order to see whether the activation of Pdgfrα was ligand-dependent, the expression of the 
Pdgfrα-specific ligands- Pdgfa, Pdgfb and Pdgfc were analyzed by qRT-PCR. Indeed, the 







Figure 10. Tumors of Ptch mutant mice overexpress Pdgfrα and its ligands. (A and B) Western Blot 




 mice using anti-Kit, anti-Pdgfrα 
and anti-pPdgfrα (phosphorylated Pdgfrα) antibodies. GIST-T1 and NIH/3T3 cells were used as control 
samples. (C) qRT-PCR analysis of Pdgfa, Pdgfb and Pdgfc in normal intestine and in tumors. Expression levels 
in tumors are shown in relation to normal intestine, which was set=1. (black bars: intestine; grey bars: tumors).  




 mice are negative for 
Kit and Pdgfrβ but strongly overexpress Pdgfrα. In addition, Pdgfrα seems to be active in the 
tumors, which correlates with high expression of the Pdgfrα ligands. 
5.2.3 Activation of Hh signaling in gastrointestinal tumors of Ptchflox/floxLysMcre+/- mice 
 
Next, the Hh activity in the tumors was investigated. As explained in the introduction section, 
tumors associated with Ptch mutations are expected to show activation of the Hh signaling 
pathway. Since a reliable marker for Hh pathway activity is the expression of Gli1, tumors 
and corresponding normal intestine were subjected to a Gli1-specific qRT-PCR analysis. The 




intestine (Figure 11). In addition, the expression of the two other Gli transcription factors Gli2 
and Gli3 was analyzed. Although the expression of these two genes was increased in 
comparison to the small intestine, the increase did not reach statistical significance. Besides 
Gli1 the tumor samples also overexpress mutant Ptch
del 
transcripts when compared to normal 
intestine (Figure 12A and B). This was revealed by RT-PCR (Figure 12A; in the mutant 
Ptch
del 
transcripts exon 7 is spliced into exon 10 due to the cre-mediated deletion of exon 8 
and 9 of the Ptch gene) and by in situ hybridization (Figure 12B). The latter method 
confirmed that the tumors overexpressed Gli1 and additionally shows that wt Ptch transcripts 
are missing, whereas the mutant Ptch transcripts are strongly overexpressed in the tumors 
(Figure 12B). Consistent with an aberrant Hh pathway activation in tumor cells, the normal 
intestine only showed a few cells positive for Gli1 or Ptch.  
 
 
Figure 11. Gli expression in tumors of Ptch mutant mice. Quantitative RT-PCR analysis of Gli1, Gli2 and 




 mice. Expression levels (± SEM) in 
tumors are shown in relation to normal intestine, which was set to 1. Grey bars: intestine; black bars: tumors. 






Figure 12. Activation of Hh signaling in tumors of Ptch mutant mice. (A) RT-PCR analysis of tumors 
showing the disappearance of wt Ptch (731 bp) and the appearance of the Ptch
del 
(451 bp) transcript. Similar 
results were obtained by in situ hybridization of the Hh target genes Gli1 (B, upper panel) and Ptch (B, lower 
panel). The 477 bp Ptch probe identifies both the wt and the mutant Ptch
del
 transcripts (B, lower panel left), in 
which exon 7 is spliced to exon 10 due to cre-mediated deletion of exon 8 and 9. The 250 bp Ptch probe 
exclusively binds to wt Ptch transcripts (B, lower panel, right). The figure demonstrates that the tumors 
overexpress exclusively mutant Ptch
del
 transcripts, since wt Ptch transcripts were not detected. Scale bar in μm: 
200. 
These data indicate that the Hh signaling pathway is activated in the tumors but not the 





5.3 Differentiation of the tumors of Ptchflox/floxLysMcre+/- mice from LMS 
5.3.1 Comparison of gene expression profiles between human GIST, human and 




 mice  
 




 mice strikingly 
resembled GIST tumors in humans. Since LMS is an important tumor entity in the 









According to the GEO database, GIST overexpress the main HH targets PTCH (4-fold) as 
well as other downstream HH target genes FOXF1 (20-fold), HAND2 (2-fold) and NKX3.2 
(130-fold) when compared to LMS (Figure 13).  
 
Figure 13. According to the GEO database, GIST overexpress HH target genes when compared to LMS. 
Data are from GEO GDS1209 (http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS1209). 
Due to the data from GEO database, the expression levels of the Hh downstream target genes 








 mice and in murine LMS derived from Pten/p53 double-mutant mice 
(ref 
126
 and Guijarro and Hernando, unpublished). The data was compared to 20 human GIST 
and 7 human LMS samples. The human tumor samples were from the Department of 
Pathology at the Leiden University Medical Center. Indeed, the analysis showed higher 
levels of the Hh target genes GLI2/Gli2, PTCH/Ptch, HAND1/Hand1, FOXF1/FoxF1 and 




 mice when compared to the 
respective LMS samples (Figure 14; an expression analysis of murine Nkx3.2 was not 
possible in our hands). 
 
 
Figure 14. Differentiation of the tumors from LMS. Quantitative qRT-PCR analysis of HH/Hh-target genes 





mice (Tu) compared to murine LMS derived from mice harboring a Pten/p53 mutation (lower panel). 
Expression levels in human and murine samples were normalized to the expression of β-actin and 18S rRNA, 
respectively. Data shows Box-Whisker-Plots of the relative gene expression. (*P<0.05, **P<0.01, ***P<0.001 
by unpaired t-test). 
Together, these data demonstrate that HH/Hh signaling activity is increased in human GIST 




 mice when compared to human and murine 




 mice are 
GIST-like rather than LMS-like.  
 





and thus correlated with active Hh signaling, we next analyzed the correlation between high 
PDGFRA expression and HH-signaling activity in human GIST.  
To this end, the published microarray data set GSE8167 (accession number at the GEO 
database 
127
) was analyzed by our collaborators of the Department of Medical Statistics, 
Annalen Bleckmann and Tim Beissbarth. Indeed, in this set a relation between PDGFRA 




distinguished using a cut-off according to the median gene expression of PDGFRA. Gene set 
enrichment analysis (GSEA) revealed that HH pathway genes are enriched in the PDGFRA-
high expressers (Figure 15; enrichment score according to Wilcoxon and Kolmogorov-
Smirnov test: p=0.01811 and p=0.04923, respectively). 
 
 
Figure 15. Positive correlation between HH signaling and PDGFRA expression in human GIST. 
Enrichment plot in PDGFRA high-expresser GIST samples (performed on GEO database set GSE8167): shown 
is the profile of the running enrichment score and the positions of the Hh pathway gene set members on the rank 
ordered list. 
 
Next, GIST with a known KIT and PDGFRA mutational status were analyzed for the 
expression of PDGFRA and the HH target GLI1 (for samples see Table 20). As shown in 
Figure 16 (left panel), tumors showing high PDGFRA expression are PDGFRA mutant GIST. 
This was in agreement with recently published data
128, 129
. Importantly, as revealed by GLI1 
expression, PDGFRA mutant GIST generally show higher HH signaling activity when 
compared to KIT mutant or wildtype GIST (Figure 16, right panel). Thus, the positive 
correlation between HH activity and PDGFRA expression and the mutational status of 






Table 20. Characteristics of human GIST used for analysis. 
Case no. KIT/PDGFRA mutation  
24 KIT deletion N579 
26 KIT point mutation V559D 
1936 KIT point mutation V560D  
1964 KIT duplication PTQLPYDHKWEFP573-585  
1984 KIT point mutation V560D  
2594 KIT deletion WK557-558 
2648 KIT insertion AY502-503  
2822 KIT point mutation W557R 
2833 KIT point mutation W557G 
2860 KIT deletion WKVVE557-561 and point mutation D820Y 
2932 KIT deletion WK557-558 
2970 KIT point mutation V822K 
3033 KIT insertion AY502-503 
4 PDGFRA point mutation D842V  
9 PDGFRA point mutation D842V  
484 PDGFRA point mutation D842E and deletion IMHD843-846  
485 PDGFRA point mutation V561D  
486 PDGFRA point mutation D842V 
508 PDGFRA point mutation D842V 
1468 PDGFRA point mutation D842V 
12 KIT wildtype E 9, 11, 13, 17; PFDGFRA wildtype E 12, 18  
13 KIT wildtype E 9, 11, 13, 17; PFDGFRA wildtype E 12, 18  
1971 KIT wildtype E 9, 11, 13, 14, 17; PDGFR wildtype E 12, 18 
2014 KIT wildtype E 9, 11; PDGFR wildtype E 12, 18 
2272 KIT wildtype E 9, 11, 13, 14, 17 ; PDGFR wildtype E 12, 18 
3500 KIT wildtype E 9, 11; PDGFR wildtype E 12, 18  
2014 KIT wildtype E 9, 11; PDGFR wildtype E 12, 18 







Figure 16. HH activity is increased in PDGFRA mutant GIST that highly express PDGFRA. Figure shows 
qRT-PCR analysis of PDGFRA (left panel) and of the main HH-target GLI1 (right panel) in GIST that are either 
wildtype or KIT mutant (wt/KIT mut) or have a PDGFRA mutation (PDGFRA mut). The samples used for the 
study are shown in Table 20. Data is represented by Box-Whisker-Plots. 




 mice are indeed 
GIST-like rather than LMS-like. In addition, they confirm the previously reported data 
showing that HH signaling is aberrantly activated in human GIST 
46
. Furthermore, the data 
showed that PDGFRA mutant GIST have relatively high PDGFRA and GLI1 expression 
indicating increased HH activity in comparison to wt or KIT mutant GIST.  
5.3.2 Gastrointestinal tumors of Ptchflox/floxLysMcre+/- mice are responsive to imatinib 
 
An important characteristic of most human GIST is the responsiveness to imatinib, which 
inhibits the activity of both the KIT and PDGFR tyrosine kinases 
130
. Therefore, the effect of 





mice. For this purpose, 6 or 8 week old mice were randomly divided into 6 groups. The first 2 
groups received 0.1g/kg/day imatinib orally over a period of 10 or 12 weeks. One additional 
group received the same dose (0.1g/kg/day) for 10 weeks and was observed for 3 additional 
weeks before autopsy. All 3 imatinib-treated groups had a corresponding vehicle-treated 
control group. All the treatment schemes were tolerated well by the animals. When the 
animals were sacrificed and subjected to autopsy all mice included in the analysis have 
developed GIST-like tumors. Both the 10 and 12 week treatment decreased the total number 
of tumors: Whereas the average tumor number was 5.2 ± 1.7 and 5.2 ± 1.5 in the vehicle-
treated groups, imatinib treatment for 10 or 12 weeks significantly decreased the number of 
tumors to an average of 2.6 ± 1.3 (P=0.01) and 2.6 ± 1.3 (P=0.0080) per animal, respectively 
(Figure 17 and Table 21). In addition, the effect of imatinib seems to be reversible when the 




imatinib-treated animals had a comparable tumor number when compared to the vehicle-
treated mice with 4.0 ± 1.73 and 5.0 ± 3.61 tumors per mouse, respectively (Table 21). The 




 mice can be attributed to the 









 mice respond to imatinib treatment. Shown are representative 




 mice after treatment with vehicle (left) or imatinib (right). Imatinib treatment 
decreased the number of tumors (also see Table 21) in comparison to vehicle-treated animals. 
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 3 174 0.1g/kg/d imatinib orally starting at 
8 weeks of age for 10 weeks plus 3 











 3 174 vehicle (200 μl PBS) orally starting 
at 8 weeks of age for 10 weeks plus 




: 5.0 ± 
3.61 
1 from birth on  




5.4 GIST-like tumors of Ptchflox/floxLysMcre+/- mice are derived from LysM+ cells of the 
GI tract 
 
The histology, the localization within the gut wall, the development i.e. in the same location 
as do tumors in mice overexpressing a Kit K641E mutation (normally found in the caecal 
area), and the responsiveness to imatinib were suggestive of GIST 
131
. However, this was 
inconsistent with the Ptch deletion in the myeloid lineage, as GIST are considered to arise 
from KIT- or PDGFRA-expressing precursor cells of the smooth muscle layer of the GI tract. 




 mice were 



















, LysMcre not only induces recombination at the Ptch
flox
 
locus, but also at the R26R locus. Therefore, all progeny of LysM-expressing cells are 
expected to be marked by the permanent expression of LacZ. As demonstrated in Figure 18, 













not only induces recombination at the Ptch
flox
 locus, but also at the R26R locus. This marks LysM
+
 cells by 







mice. Left: HE staining, Right: LacZ staining. Dotted line marks the tumor (Tu)/normal muscle border. Scale 
bar (μm):500. 
In order to assess whether the LysM-positive tumor cells were derived from the BM, yet 


















 mice lack T, B and natural killer cells 
132
, the successful 
repopulation of the mice with donor BM was monitored by flow cytometry analysis of T and 













 mice were successfully repopulated with the 






 control mice (Figure 19). 





mice did not develop any tumor, not even after 250 days post-transplantation. Thus, these 
data suggested that the GIST-like tumors did not originate from LysM
+ 























 mice were 




 mice. After 6 weeks, peripheral blood cells were 
analyzed by flow cytometry. Cells were analyzed by staining with antibodies against either CD3 or TCRβ to 
identify the T cell population, and antibodies against B220 and CD19 to identify the B cells.  




 mice were derived 
from a LysM
+





mice where stained for LacZ. Indeed, as shown in Figure 20, LacZ-positive cells 
were detected between the longitudinal muscle layer and the serosa, and between the circular 
and the longitudinal muscle layers (Figure 20) i.e these cells were detected in the same 










 mice. In the 
muscularisLacZ-positive cells are detected between the longitudinal muscle layer and the serosa (left panel) and 
the circular and longitudinal muscle layer (right panel). Scale bars (μm): 50. 
Together, these data suggested that Ptch-associated GIST are derived from a BM-independent 
LysM
+
 cell population in the muscular wall of the intestine. 
5.4.1 LysM+ cells of the GI tract can express Pdgfrα but not Kit 
 




 mice had a GIST-like appearance and expressed 
Pdgfrα but not Kit, we hypothesized that the respective cell of origin i.e. the LysM
+
 cell in 
the intestinal wall, also should express Pdgfrα but not Kit. In order to prove this assumption, 
the expression status of Kit and Pdgfrα in LacZ
+ 






mice was investigated. Immunohistochemical analyses revealed that some 
LacZ
+
 cells in the muscle layer co-expressed Pdgfrα (Figure 21, left and middle panel). In 
contrast, no LacZ
+
 cells expressing Kit were detected. However, the LacZ
+
 cells frequently 
were juxtapposed to Kit
+





 mice were not derived from LysM
+
 cells that concomitantly 




 mice originate from LysM
+
 cells that 













mice. Sections were co-stained with antibodies against Pdgfrα (left and middle panel) or Kit (right 
panel). Inset in the left panel shows a LacZ-positive, but Pdgfrα-negative cell. Inset in the middle panel shows a 
LacZ/Pdgfrα double-positive cell. Inset in the right panel shows a LacZ-positive cell juxtaposed to a Kit-
positive cell (a similar cell is marked by an arrowhead). The asterisk in the right panel indicates a LacZ-positive 
muscle fiber not juxtaposed to Kit-positive cells. Scale bars (μm): left and middle panel: 50; right panel: 25. 
Still another question was of whether Hh signaling was activated in LysM
+









 mice. This was expected since the Ptch mutation 
in LysM-expressing cells was the driving force for tumor development. To answer this 







for Pdgfrα (by IHC) or LacZ with either the Gli1 or Ptch in situ probes (see 4.12.5 and 
4.12.6). However, this was not possible in my hands. Nevertheless, the Gli and Ptch in situ 
hybridization of intestines derived from wt
 
mice showed that the distribution of Gli1-positive 




 cells i.e. they were 
found between the serosa and the longitudinal muscle layer, the longitudinal muscle layer 
and the circular muscle layer and within the circular muscle layer. A representative staining 
using the 477 Ptch probe (see 4.12.5) is shown in Figure 22. 
 


















 cells. In situ hybridization 
of Ptch in the normal intestine of a wt mouse using the 477 bp Ptch probe. The figure demonstrates Ptch 
expression in single cells (shown by arrows) between the serosa (ser) and the longitudinal muscle layer (LM) of 
the normal intestine, the LM and the circular muscle layer (CM) and within the circular muscle layer. Scale bar 
in μm: 20. 
5.5 HH signaling cooperates with PDGFRA signaling, but not with KIT signaling, in 
cellular transformation 
 




 mice were 
derived from a LysM
+
 cell of the intestine, in which Hh signaling was activated due to 
mutations in Ptch. In addition, this cell may express Pdgfrα, but not Kit.  
 
Recently it has been shown that HH signaling frequently cooperates with other signaling 




. The positive correlation of the expression and 
activation of PDGFRA and HH signaling in the GIST array data set (see Figure 15) as well as 
the potential activation of Hh signaling in Pdgfrα
+





 mice prompted us to test the possibility of signal cooperation between 
Hh and Pdgfrα signaling in oncogenic transformation. For this purpose, human non-
tumorigenic HaCaT keratinocytes expressing GLI1 under the control of Dox-inducible 
promotor (Dox-inducible GLI-HaCaT were employed. This is a well established assay system 
that facilitates analysis of proteins that modulate the oncogenic activity of GLI proteins 
112
. 
HaCaT keratinocytes were seeded on plates with agar and treated with Dox and/or the 
PDGFRA ligand PDGFB. To assay a possible cooperation of HH/GLI with KIT signaling, the 
same GLI1-expressing HaCaT cells were stably transduced with the constitutively active 
D816V KIT mutant. The codon 816 in exon 17 is a mutation hot spot for KIT gene and one of 






The data revealed that the Dox-induced expression of GLI1 cooperated with the PDGFRA 
ligand PDGFB to induce cellular transformation. This was evidenced by significant growth 
of the transformed cells in 3D cultures (Figure 23, left panel). By contrast, neither GLI1 nor 
PDGFB alone was able to elicit appreciable growth. As PDGFB induced phosphorylation of 
PDGFRA (Figure 23, right panel) and activated both ERK and the JUN oncogene, we 
conclude that PDGFRA signaling can cooperate with HH/GLI in oncogenic transformation. 
In contrast, simultaneous expression of GLI1 and dominant active KIT (D816V mutant) did 
not enhance transformation (Figure 23, left panel). These data suggest that Pdgfrα, in 







Figure 23. HH signaling cooperates with PDGFRA signaling in cellular transformation. (Left panel) 
Quantification of anchorage-independent clonogenic growth of human non-tumorigenic GlI1-HaCaT 
keratinocytes after activation of either HH signaling (by Dox treatment; see text GLI1)) or KIT signaling 
(overexpression of the constitutively active Kit D816V mutant; KIT) or stimulation of PDGFR signaling by 
PDGFB. Either signal alone has little or no activity towards cellular transformation, whereas GLI1 in 
combination with PDGFB treatment (GLI1/PDGFB), but not in combination with KIT activation (GLI1/KIT), 
leads to formation of clonogenic colonies (spheres) in 3D cultures (asterisks indicate p<0.03 by unpaired t-test). 
(Right panel) Western Blot analysis of HaCaT cells after incubation with PDGFB using anti-Pdgfrα and anti-p-
Pdgfrα (phosphorylated Pdgfrα) as well as anti-Erk, anti-p-Erk(1/2) (phospho-Erk1/2), anti-Jun and anti-p-Jun 





Next we tested whether the cooperative effect was also apparent in a xenograft assay. For this 
purpose GLI1-HaCaT cells were retrovirally transfected with PDGFRAH650Q 
(PDGFRA
mut
). The PDGFRAH650Q mutation results in phosphorylation and activation of 
PDGFRA, but shows only weak intrinsic transforming activity 
135
. This characteristic 
ensured that the potential cooperative transforming activity was not overlooked, what might 
have happened when expressing a PDGFRA mutation with strong transforming activity. 
Therefore, this mutation was more suitable for studying potential cooperative transforming 
effects than PDGFRA mutations with strong transforming activity.  
 
To see whether this in vitro transformation led to tumor growth in vivo, 1x10
6 
GLI1-HaCaT 
cells transfected with PDGFRA
mut
 were injected s.c into the hind flank of nude mice. As 
controls, GLI1-HaCaT cells or HaCaT cells transfected with PDGFRA
mut
 transfection were 
also transplanted. To induce and maintain GLI1 expression in the xenografts, Dox (10 mg/ml) 
was added to the drinking water supplemented with 5% sucrose. The tumor growth was 
monitored for 24 days. The in vivo tumor growth analysis revealed that in comparison to 
growth induced by GLI1 and PDGFRA
mut
, the growth of GLI1-PDGFRA
mut
 cells were 
strongly enhanced. These data show that PDGFRA signaling in cooperation with GLI1 
strongly increased growth of GLI1-HaCaT transfected with PDGFRA
mut
. Altogether, these 






Figure 24. HH signaling cooperates with PDGFRA signaling in cellular transformation in vivo. (A) 
Westernblot analysis of PDGFRA expression in GLI1-HaCaT keratinocytes expressing GLI1 under the control 
of a Dox-inducible promotor. Retrovirally-expressed PDGFRAH650Q (PDGFRA
mut
) results in overexpression 
of PDGFRA. Lane 1: control-transduced GLI1-HaCaT; Lane 2: control-transduced GLI1-HaCaT + Dox; Lane 
3: PDGFRA
mut
-transduced GLI1-HaCaT; Lane 4: PDGFRA
mut
-transduced GLI1-HaCaT + Dox. The cell line 
GIST-T1 and GIST-like tumor (Tu) were used as control samples. (B) In vivo tumor growth analysis of Dox 
inducible GLI1-HaCaT cells transduced with constitutively active PDGFRA (PDGFRA
mut
) or empty vector 
control (n=6 for each setting). Cont: tumor growth in control mice injected with control-transduced inducible 
GLI1-HaCaT cells without Dox treatment (i.e. no GLI1 expression), GLI1: tumor growth of inducible and 
control-transduced GLI1-HaCaT cells in mice treated with Dox. PDGFRA
mut
: tumor growth of PDGFRA
mut
-
transduced inducible GLI1-HaCaT without Dox treatment (i.e. PDGFRA
mut
 only). GLI1/PDGFRA 
mut
: tumor 
growth of PDGFRA 
mut
-transduced inducible GLI1-HaCaT in Dox treated mice (***P<0.001 by Dunnett´s 
multiple comparison test). 
5.6 Functional analysis of immune cells of Ptchflox/floxLysMcre+/- mice  
 
Another line of investigation dealt with the functional analysis of Ptch-deficient cells of the 
innate immune system. Although the blood analysis shown in section 5.1 did not reveal any 








it was possible that the function of LysM-expressing cells ( i.e. of granulocytes, macrophages 




 mice.  
In immune cells, Hh components are expressed in B and T cells as well as in myeloid cells. It 
is now established that Hh signaling plays an important role in the differentiation and 
proliferation of early thymocyte progenitors, and also in modulating T cell receptor signaling 
during repertoire selection, with implications for positive selection for CD4 versus CD8 
lineage commitment, and clonal deletion of autoreactive cells (reviewed in
136
). Recent data 
showed that Hh signaling is dispensable for B cell development but that the Hh pathway 
within stromal cells promotes B lymphopoiesis in a non-cell-autonomous fashion 
137
 (see also 
introduction). However, very little is known about the role of Hh signaling in myeloid cells 
and almost no data are available about its role in innate immunity.  
 







 control mice to TLR activation. Activation of TLR not only leads to the induction 
of inflammatory responses but also to the development of antigen-specific adaptive immunity. 
The TLR-induced inflammatory response is dependent on a common signaling pathway that 






In order to mimic TLR-induced inflammatory responses in Ptch-deficient BMDM, I used 
bacterial lipopolysaccharide (LPS) and Pam3CSK4 (BLP). LPS is an essential component of 
the surface of gram-negative bacteria that activates the TLR 4 receptors which is present on 
the surface of many myelomonocitic cells. In contrast BLP is a triacylated lipopeptide that 
elicits responses mediated by TLR 1/2. 
In order to study the role of Ptch-deficient macrophages (and other myeloid cells) in tumor 





First, I transplanted the syngeneic B16F10 melanoma cell line and ID8-LUC ovarian 




 and control Ptch
flox/flox
 mice and monitored the 
tumor growth. In the case of the ovarian carcinoma model, I analyzed the expression of the 
M2 macrophage markers Arg1 and Trem2 in the tumor environment and the splenic 
recruitment of macrophages and granulocytes. Secondly, I chemically induced skin tumors 
using the two-step chemical carcinogenesis (DMBA/TPA) method and analyzed tumor 
growth and proliferation of the treated skin as well as the recruitment of macrophages and T 





It should be emphasized that the presented results, especially those of the in vitro 
experiments, are only preliminary. The respective experiments have to be repeated in the 
future. 
5.6.1 Analysis of Ptch-deficient BMDM  
 







 control mice were isolated as described in section 4.11.1. 




 were Ptch-deficient, recombination 
assay was performed. The results showed that almost 100% of BMDM were recombined at 





 mice remained comparable to BMDM derived from Ptch
flox/flox
 mice 
(Figure 26). This indicates that the Ptch mutation in BMDM apparently did not result in 
activation of Hh-signaling.  
 
 





















 mice is not overexpressed. 
Quantitative PCR analyses showed no difference in the expression of Gli1 (left panel) and Ptch (right panel) in 






 mice. The data show the mean values (± SEM). 
After having shown that BMDM are indeed recombined at the Ptch locus, the cells were 
treated with 100 ng/ml LPS to see whether Ptch has a role in inflammatory response. First it 
was assessed whether the metabolic activity of BMDM was influenced by Ptch-deficiency 








control mice were incubated with 100 ng/ml LPS for 24 h and subjected to a WST-
1 assay. The reduction of WST-1 results in a colored formazan compound that can be 
measured via colorimetric measurement (at A450nm) and is a direct parameter of the cellular 
metabolic activity and viability. As shown in Figure 27, the Ptch mutation did not influence 
the basal metabolic activity when compared to wt cells. It also did not influence the viability 
of the BMDM after LPS stimulation.  
 







 control mice with or without stimulation with LPS (100 
ng/ml) at different time points (6, 12 and 24 h). WST-1 reagent was added 4 h before absorbance reading. Grey 
bars: Ptch
flox/flox
















control mice with or without LPS stimulation were quantified by ELISA. As 
shown in Figure 28, the cytokines IL-10 and IL-12p40 and chemokines KC (CXCL1), MCP-
1 (CCL2) and MIP1-a (CCL3) as well as the pro-inflammatory cytokines RANTES (CCL5), 







mice. However, Ptch did not influence the release of the 
cytokines and chemokines because the values between Ptch-deficient and Ptch-wt BMDM 
were almost identical (Figure 28). These data clearly demonstrate that the Ptch mutation did 




Figure 28. Ptch-deficiency does not influence cytokine release of BMDM. BMDM were treated with 100 ng 
LPS/ml or solvent. Supernatants were collected after 6, 12 and 24 h of incubation. The concentrations of 









To check whether the dose of LPS may have an effect on the BMDM's cytokine release, the 
pro-inflammatory cytokines RANTES, TNFa and IL-6 as well as IL12p40 were examined. 
ELISA showed that 1 to 100 ng/ml of LPS stimulated the release of all cytokines. There was 
no strong dose-dependency of the release of the cytokines at any time point examined. Again, 






Figure 29. Ptch does not influence the dose-dependent response of BMDM after LPS stimulation. 
Quantification of the cytokine release after stimulation with different doses of LPS (1, 10 and 100 ng/ml) was 
done by ELISA. The supernatants were collected at different time points (6, 12 and 24 h after stimulation). The 
data are expressed as mean ± SEM. Grey bars: Ptch
flox/flox





In a parallel approach, the mRNA expression levels of the cytokines TNFa, IL-6 and 
RANTES were investigated in BMDM after stimulation with LPS. These cytokines were 
chosen since these are the most common read-outs for a pro-inflammatory response. As 
shown in Figure 30, stimulation with LPS resulted in increased levels of TNFa, IL-6 and 
RANTES. The effects of LPS were strongest on RANTES transcription and weakest on IL-6 
transcription. In addition, the data indicate that the factors are regulated in a dose-dependent 
manner. However, no significant differences between Ptch-deficient and control BMDM 
were observed. These data correlated with the ELISA data, showing that Ptch-deficiency also 





Figure 30. Ptch-deficiency does not affect TNFa, IL-6 and RANTES mRNA expression in BMDM. 







 mice 12 h after LPS stimulation (100 ng/ml). Grey bars: 
Ptch
flox/flox






Taken together, these data suggest that Ptch-deficiency does not influence cytokine 
production in BMDM, even not after stimulation with LPS. 
Next, Ptch-deficient and control BMDM were treated with BLP. In contrast to LPS, BLP is a 
TLR1/2 agonist and possibly exerts its inflammatory activity by additional activation of TNF-
dependent macrophage-specific mechanism as shown in inflammatory disease models 
141
. 
Interestingly, the stimulation of the BMDM for 24 h with 100 ng/ml BLP resulted in a 
significant 2-fold (P=0.13) upregulation of IL-6 mRNA expression levels in the Ptch mutant 
BMDM when compared to the wt control. The expression levels of the two other cytokines 
RANTES and TNFa remained comparable between the two genotypes (Figure 31). However, 






Figure 31. Ptch-deficiency increases the IL-6 expression of macrophages after BLP treatment. Quantitative 






 mice showed no difference in the 
expression of RANTES and TNFa after a 12 h stimulation with 100 ng/ml BLP. However, the BLP treatment 




 mice. Grey bars: 
Ptch
flox/flox





Finally, the BrdU-incorporation rate of Ptch-deficient and wt BMDM was analysed both with 
and without stimulation with either LPS or BLP. In a first experiment, cells were stimulated 
with the TRL agonists for 48 or 72 hours. The rationale for this relatively long incubation 
time is the fact that macrophages are relatively slow-proliferating cells compared to most 
other cells. The basal BrdU-incorporation rate (without the LPS or BLP stimulus) did not 







cultured for 48 h and 72 h (Figure 32; P=0.61 and P=0.098 for 48 h and 72 h, respectively). 
However, the stimulation with both LPS and BLP for 72 h revealed a striking difference 
between the genotypes: Although after that time, both Ptch mutant and Ptch control BMDM 
showed a significant decrease in growth, the decrease was significantly more pronounced in 
BMDM derived from Ptch
flox/flox
 mice (Figure 33, P=0.04). This significant effect was already 
seen after 48 h in the BLP treated group (Figure 34, P=0.003). Unfortunately, thus far I have 
not analysed apoptosis or metabolic activity of BMDM after treatment with BLP or LPS for 
48 h or 72 h. Therefore it is hard to tell whether the above-mentioned differences in BrdU-
incorporation indeed mirror a different proliferative capacity of Ptch-deficient BMDM or 












 mice were cultured for 48 h or 72 h. 20 h before the end of the 
experiment, BrdU was added to the cells. BrdU incorporation was measure using a luminometer. BrdU-
incorporation rate of BMDM isolated from Ptch
flox/flox
 mice was set to 100%. Assay was done in triplicates and is 
presented as mean values ± SEM. P =0.61 and P= 0.098 for 48 and 72 h, respectively. 
 
 
Figure 33. Ptch-deficiency modulates the BrdU-incorporation rate of LPS-stimulated macrophages. 
BMDM derived from Ptch
flox/flox




 (black bars) mice were treated with 100 
ng/ml LPS for 48 or 72 h as indicated. 20 h before the end of treatment, BrdU was added to the cells. BrdU-
incorporation was measure using luminometer. BrdU-incorporation rate of untreated cells was set to 100%. 








Figure 34. Ptch-deficiency modulates the BrdU-incorporation rate of BLP-stimulated macrophages. 
BMDM derived from Ptch
flox/flox




 (black bars) mice were treated with 100 
ng/ml BLP for 48 or 72 h. 20 h before the end of treatment, BrdU was added to the cells. BrdU incorporation 
was measure using luminometer. BrdU-incorporation rate of untreated cells was set to 100%. Assay was done in 
triplicates and presented as mean values  ± SEM. **:P=0.003; *: P=0.012.  
5.6.2 Effects of Ptch-deficient LysM+ cells on tumor surveillance 
 
As already explained in the introduction section, macrophages, granulocytes and DC (i.e. the 
main cell lineages in the mouse that express LysM) play an important role in tumor 







mice were transplanted s.c. with the syngeneic 
melanoma cell line B16F10. After transplantation, tumor growth was measured every day 
using a caliper. Tumor volume was calculated using the formula L×W
2
×0.4. When the tumor 
volume of the animals reached ≥ 2cm
3
 the animals were sacrificed due to the general 
condition of the mice because of the heavy tumor burden. As seen in Figure 35, all animals 
included in the study developed melanoma and the tumor growth rate was not influenced by 






Figure 35. Ptch-deficiency in LysM
+
 cells does not influence the growth of B16F10. Animals were injected 
s.c. with 10
4 
B16F10 melanoma cells. Kaplan-Meier curve shows the cumulative incidence of tumors larger 
≥2cm
3
. Tumor growth was monitored every day using a caliper and the tumor area was calculated as explained 
in the text. The animals were euthanized when tumors reached ≥2cm
3















 animals. According to the literature this should result in homing of the 
B16F10 cells to the lung, which is frequently referred to “metastasis” 
142
. Twenty days after 
transplantation of the cells, the lungs of the mice were subjected to autopsy and tumor 




 animals have more tumor 
nodules in the lungs (5.0 ± 8 nodules/lung) when compared to Ptch
flox/flox
 control animals (2.5 
± 2 metastasis nodules/lung). However, these differences were not significant (Figure 36, 
P=0.45 by t-test). Together, these data suggest that Ptch-deficiency in LysM
+
 cells does 
affect neither local nor metastatic B16F10 melanoma growth. 
 
Figure 36. Ptch-deficiency in LysM
+







(n=7) mice were injected i.v. with 1x10
5
 B16F10 cells. Twenty days 
post-injection, animals were sacrificed and lungs were analyzed for tumor numbers. Box plots show mean 













 mice to have a higher tumor load in the 
lungs after transplantation of B16F10 cells, we also transplanted ID8-LUC cells. The ID8 
cell line is an ovarian carcinoma cell line derived from C67Bl/6 mice and is rather slow-
growing. Due to the slow-growing nature of this tumor cell line, we hoped to not overlook 
small differences in tumor growth, which might have occurred during the studies using the 
fast-growing tumor cell line B16F10. 
 
ID8-LUC cells were injected i.p. into the peritoneal cavity and the growth was visualized 
using a CCD camera after injection of D-Luciferin substrate. The relative luminescence 
values are proportional to the ovarian carcinoma growth in the mice. According to our 
collaboration partner Thorsten Hagemann, the injection of 1x10
7
 ID8-LUC cells should result 
in detectable tumors starting by week 4 after transplantation. Indeed, 4 weeks after 
transplantation the relative luminescence intensity increased steadily, which indicated growth 







 mice showed no significant difference between the two genotypes 
(Figure 37 and Figure 38). As demonstrated in Figure 37, the tumor growth seemed to cease 
in Ptch
flox/flox 
mice at week 7 after transplantation. Unfortunately, all mice were killed at week 
8 after transplantation and thus, it remains open whether the stagnation of tumor growth in the 
wt animals was reached. However, since all data available so far described progressive 
disease after implantation of ID8-LUC cells in wt mice 
143













 mice. ID8-LUC cells were 
transplanted into the peritoneal cavity of Ptch
flox/flox




 (▲) mice and the tumor 
growth was monitored using a CCD camera and quantification of luminescence. Data shown are the average 
luminescence units ± SEM. 
 
Figure 38. Representative bioluminescence images of mice 7 weeks after injection with ID8-LUC cells. 
Images were taken 5 min after D-Luciferin administration. Luminescence was normalized to a background 
image of the mice taken before the injection of D-Luciferin. Shown are representative pictures of pseudo 
colored overlay images of the bioluminescence signal intensity superimposed on mice. 
As already stated in the Materials and Methods section (see 4.13.9), transplantation of ID8-
LUC cells leads to the development of an ascites approximately 13 to 16 weeks after the 











ascitic fluid in the ID8-transplantation model frequently serve as a source for the analysis of 
the “tumor microenvironment” 
144
. In order to analyze the composition of the “tumor 
microenvironment” of ID8-LUC cells, the ascitic fluid of transplanted animals was subjected 
to flow cytometric and expression analyses. Unfortunately, flow cytometry for the analysis of 
the cellular composition of the ascites was not successful, since there were too many 
erythrocytes present in the ascites despite Ficoll gradient separation and/or addition of 
erythrocyte lysis buffer to the samples. Nevertheless, cells from the ascites were subjected to 
gene expression analysis to see whether Ptch influences the expression of M2 macrophage-







 animals showed that Ptch-deficiency does not influence on the 




Figure 39. Ptch-deficiency in LysM
+
 cells does not influence the expression of alternative macrophage 
markers in the tumor microenvironment of ovarian carcinoma. Quantitative PCR analysis of Arg1 and 






 mice. Shown are mean ± SEM. 
Grey bars: Ptch
flox/flox





To this end, flow cytometric analysis of the spleen during ascites formation was carried out. 
The splenic granulocytes (Gr-1
+ 
cells) and macrophages (CD11b
+
 cells) have been 













represent myeloid-derived suppressor cells (MSDC) 
145
. 
A previous report showed that MDSC derive from the ascites and the spleen in mice 
lymphoma tumor model had similar morphology and phenotype 
146
. Moreover, the spleen 
acts as a reservoir of granulocytes, tumor-associated macrophages and MDSC during tumor 
progression 
147




granulocytes, tumor-associated macrophages and MDSC in the tumor- microenvironment.  
The analysis revealed that Ptch has no impact on the numbers of splenic MDSC (Figure 40) 
or granulocytes and macrophages (Figure 41). These data suggest that Ptch does not 
influence tumor growth by modulation of these cell populations. 
 
 
Figure 40. Ptch in LysM
+


















Figure 41. Ptch mutation does not influence the number of granulocytes and macrophages in the spleen. 
Flow cytometry analysis of splenic Gr-1
+
 granulocytes and CD11b
+
 macrophages did not reveal a difference 






mice. Grey bars: Ptch
flox/flox










 mice does 
neither influence the expression of Arg1 and Trem2 in the tumor microenvironment of ovarian 




) or MSDC numbers 









The two-step chemical tumorigenesis model using DMBA/TPA has been widely applied to 
study initiation, promotion and progression (malignant conversion) of mouse skin tumors 
148
. 
Initiation of the skin tumors is accomplished with one single dose of DMBA. Continuous 
TPA treatment twice per week further results in tumor promotion and finally resulting in the 
development of papilloma, SSC and melanoma-like nevi in mice.  







animals. Development of papillomas was closely monitored twice per week and only 







 control mice developed papillomas. The data represent 
the number of papilloma at the end of the study. Although the control Ptch
flox/flox
 animals 





 mutant mice (2.38 ± 0.96 papillomas/animal) (Figure 42) the 
difference was not significant (P=0.34). In addition, the time span until the appearance of the 
first papilloma was monitored. The first papillomas were noticed after 13.8 ± 5.5 weeks in 
Ptch
flox/flox





 mice. However, this difference was also not significant between the two 
genotypes (Figure 42; P=0.27). 
 







mice. Tumor initiation with DMBA and tumor promotion with TPA for 
220 days resulted in papilloma in both Ptch mutant and control animals Left panel shows the average number of 
visible papilloma (ca.≥1 mm in diameter) that has developed per animal in the DMBA/TPA treated skin area at 
the end of the study. In the right panel the time at which the papillomas first became visible (ca.≥1 mm in 




Although there was no difference in the papilloma number in both cohorts, the DMBA/TPA 




 mice. Indeed, the 
epidermis of these mice was significantly thicker in comparison to the controls (Figure 43A; 
P=0.03). The skin thickness of DMBA/TPA treated skin samples was analyzed as described 
in the Material and Methods section (4.12.8). Furthermore, IHC staining for the proliferation 





 skin (27.01 ± 2.38% out of 1000 cells counted) compared to Ptch
flox/flox
 
skin (23.34 ± 3.09% out of 1000 cells counted). However, the difference in the percentage of 
Ki-67 positive cells did not reach statistical significance (P=0.21; Figure 43B). 
 
 






mice. (A) Skin thickness of the animals after tumor initiation with DMBA and tumor promotion with TPA for 
220 days. For each site of skin, the thickness of the epidermis (from the basal layer up to the stratum granulosum 
but excluding the stratum corneum was measured using the Cell F program. (B) The figure shows the percentage 
of Ki-67
+
 cells in the epidermal layer of DMBA/TPA treated skin (P=0.21). For this purpose, Ki-67 positive 
cells were counted in at 1000 epidermal cells each from at least 8 animals. The positive cells are presented as the 
percentage of the total number of counted cells. 
 
Since DMBA/TPA treatment can lead to development melanoma-like nevi, the number of the 





 (25 ± 19 nevi per animal) and Ptch
flox/flox
 (16 ± 9 nevi per 







 mice was measured using Cell F software. The contour 
of the nevi in every image taken was traced using freehand tools. The actual nevi size was 
measured as described in 4.12.8 in the Material and Methods section. The nevi size was 




samples from each animal; at least 8 animals per group) and normalization to the total area of 





 was significantly larger than that of Ptch
flox/flox
 mice.  
 







like nevi size was calculated by tracing the contour of each nevus by freehand and measured using Cell F 
program. The nevi size was calculated by summing up the individual nevus area measured from each sample (3 
skin samples from each animal; at least 8 animals per group) and normalizing it to the total area of the analyzed 
skin samples. The data shows boxplot and mean values ± SE. of 6 sections derived from atleast 8 individual 
animals per group (P=0.007).  
 







mice. Image shows HE stained mouse mice skin after tumor initiation with DMBA and 
tumor promotion with TPA for 220 days. Melanoma-like nevi cells appear as “black” cells due to high melanin 
content. Scale bar (μm): 200. 






mice was stained with 
F4/80 and MHCII to visualize the numbers of tumor-associated macrophages and DC, 
respectively. After staining with the respective antibodies the sections were scored by two 




melanoma area. The scores were ranked between + (low), ++ (intermediate) and +++ (high), 
depending on the number of positive cells in and around the melanoma area. The + score 
indicates that there were <10% positive cells, the score ++ indicates that 10-20% of cells 
were positive, while the score +++ indicates that >20% cells were positive. The results are 





 cells were recruited to the nevi after DMBA/TPA treatment. 
Interesting, whereas none of the nevi in of Ptch
flox/flox 
mice were strongly infiltrates with 
MHCII
+




mice showed a high infiltration 
with this cell population. Similarly, F4/80
+
 macrophages were low in nevi-bearing skin of all 
Ptch
flox/flox




mice showed an intermediate 
number of macrophages in and around the nevi. Finally, the sections were stained for CD3, 
which is a marker for T cells. As shown in Table 22, CD3
+
 T cells recruitment to the nevi 




mice (83%) when compared to Ptch
flox/flox
 mice (50%). 




mice with nevi showed an intermediate score for 
CD3
+
 cells, whereas the percentage of Ptch
flox/flox
 mice showing this score was 50%. These 
data indicate that T cell recruitment to the melanoma-like nevi area is stronger in Ptch
flox/flox
 





Together, the immunohistochemical analyses indicate that chemically induced melanoma-




mice are larger than those induced in Ptch
flox/flox
 mice, which 
is associated with an increased recruitment of macrophages and DC, but a decreased 
recruitment of T cells.  

















+ ++ +++ n + ++ +++ n + ++ +++ n 
Ptch
flox/flox





 54.5 36.4 9.1 11 62.5 37.5 0.0 8 83.3 16.7 0.0 6 
Immunohistochemical analysis of skin from DMBA/TPA treated animals were scored by 2 independent 
individuals; +(low): <10% of the tumor surrounding cells were positive; ++(intermediate): >10% to 20% of the 






This thesis originally aimed to elucidate the role of Ptch in macrophages. For this purpose 
Ptch
flox/flox
 mice were crossed with LysMcre mice, which express cre recombinase under 
control of the murine lysozyme M promotor. This should result in specific and highly efficient 
cre-mediated deletion of Ptch in macrophages, DC and granulocytes 
104
. Indeed, as 
demonstrated by a probe-based TaqMan assay, the Ptch deletion efficiencies in cells of the 
myeloid lineage were 65% in CD11b
+
 cells (CD11b mainly marks macrophages/monocytes, 
to a lower extent granulocytes and NK cells), 52% in whole BM and 85% in peritoneal 
macrophages, 18% in CD11c
+ 
cells (CD11c mainly marks monocytes and macrophages, 
neutrophils, myeloid DC and a small subset of lymphocytes) and 20% in Thy1.2
+ 
cells 
(Thy1.2 mainly marks T cells), i.e. the degree of recombination was similar to those reported 
for LysMcre-mediated recombination of other floxed genes 
103, 104, 149
. However, the targeted 
disruption of Ptch in mice did not lead to any disruption in the development of myeloid-





 mice. Thus, the cell count, cell morphology and other hematologic 




and control mice. Although the 





values did not reach significance. Nevertheless, this anemia could be attributed to the tumors 






These data strongly suggest that Ptch is dispensable in myeloid cell differentiation and 
development, unlike its role in lymphoid-derived cells, where it was proved to have vital a 
role in the differentiation and maintenance process of T cells 
82
. Furthermore, despite Ptch 
being a tumor suppressor gene, the data shows that Ptch inactivation in LysM
+





mice does not result in malignancies of the hematopoietic system. 
6.1 GIST-like tumors in Ptch mutant mice 
 




mice was surprising. 




mice would show a 
deregulated Hh signaling cascade, i.e. an overexpression of the Hh target genes Gli1 and 
mutant Ptch, PTCH mutations per se were not previously implicated in human GIST. In 




KIT. In addition, half of the cases which are negative for KIT mutations carry gain-of 
function mutations in the PDGFRA gene 
50, 150
.  
In addition, human GIST are considered to originate from ICC harboring gain-of-function 




 mice do not originate 
from the Kit
+






 cells localized in the muscular wall of 




 mouse model is not only the first murine model 
in which endogenous GIST develop independently of Kit mutations, but also gives insights 
into the nature of the cell of origin of GIST different from KIT
+
 ICC. In addition, this model 
implicates an important role of the HH signaling pathway in the pathogenesis of GIST in 
humans. 
6.1.1 Differentiation of the tumors from PtchfloxfloxLysMcre+/- mice from LMS  
 





human GIST on the following investigations and experiments: 
 




 mice exhibit a GIST-typical localization between 
either the circular and longitudinal muscle layer or the longitudinal muscle layer and the 
serosa of the gut wall. Moreover, the tumors were predominantly localized in the wall of the 
stomach, the colon and caecum. This location was similarly to that of GIST in mice that 
overexpress the KitK641E or KitV558del mutation originally identified in sporadic human 
GIST or in the germ line of familial GIST syndrome patients 
106, 131
. Interestingly, the 
localization of GIST in mice is different than in humans. Sporadic human GIST are most 
common in the stomach (50-60%) followed by the proximal small intestine (20-30%). 
Human GIST of the large intestine are very rare 
151
. Human patients who carry germ line Kit 
K642E mutations develop both gastric and small bowel GIST 
152
. The reason for the 
differences in the distribution of GIST between mice and humans is not clear, but it was 
proposed that the differences in the density of ICC progenitor cells (which are thought to be 
the cell of origin of human GIST) in the two different species may influence the location of 
these tumors 
131





 mice do not develop from ICC argues against this proposition. 
 
Secondly, the histology and molecular features of these tumors resemble GIST rather than 




The differentiation between GIST and LMS is important because these two tumor entities 
have different response to therapy 
153





showed the occurrence of myofilaments and were negative for GIST-specific markers such as 
Kit and CD34, they stained positive for other GIST-specific markers. These were desmin, 
Pdgfrα and importantly Dog1. The name Dog1 stands for ‘‘discovered on GIST’’ and 
encodes for a protein of unknown function. However, its expression is specific for GIST 
because it is absent in non-GIST tumors and because it is expressed in GIST independent of 
the mutation type 
154




 mice, but not LMS 
derived from Pten/p53 double mutant mice, show activation of Hh signaling. This is also 
similar to human GIST, which in contrast to LMS express the HH target genes GLI, HAND2, 
FOXM1 and others. Indeed, overexpression of HH target genes in GIST, but not in LMS, has 
not only been shown in the study presented here but also by data available in the GEO 
database. 
 




mice are responsive to imatinib. Imatinib (also 
well-known as Glivec ®) is a synthetic TRK inhibitor, which now has an established role in 
the management of CML, which arise due to a fusion protein consisting of BCR-ABL 
155
. 
Imatinib also inhibits the KIT tyrosine kinase at a concentration similar to the concentration 
required for the inhibition of BCR-ABL and can block in vitro kinase activity of both wild-
type KIT and mutant KIT isoforms commonly found in GIST 
156
. Several clinical trials have 
shown a significant response to imatinib in patients with advanced GIST 
157
. Imatinib is now 
approved for the treatment of patients with KIT-positive unresectable and/or malignant GIST. 
Indeed, imatinib has resulted in response rates of 50% for patients with GIST. Conversely, 
patients with advanced LMS do not benefit from imatinib therapy 
158
. Therefore, the 




mice indicates that they are more GIST- 
than LMS-like. 
6.1.2 GIST-like tumors of PtchfloxfloxLysMcre+/- mice express Pdgfrα, but not Kit 
 
As already indicated in the introduction section, approximately 75-80 % of GIST show KIT 
mutations and 5-10 % are driven by mutations in PDGFRA 
159
. Furthermore, several percent 










Most GIST overexpress KIT protein 
48
. The 4-6% KIT-negative GIST frequently 
overexpress PDGFRA protein and are more likely to have PDGFRA mutations 
160,150
. It also 
has been reported that KIT mutant, KIT-positive GIST additionally express low levels of 
active PDGFRA and that, vice versa, PDGFRA-positive GIST with PDGFRA mutations 
express low levels of active KIT 
161
. This indicates that, in addition to exclusive KIT and 
PDGFRA subtypes, some GIST can show activation in both pathways (either mutation- or 
ligand-dependent activation), which may replace each other in the course of tumor 
progression. 
 




mice do not overexpress Kit, but 
instead overexpress Pdgfrα. Thus, these tumors appear to constitute a first mouse model of 
the PDGFRA-positive KIT-negative GIST subtype in humans.  
 




 model may have been induced by 
aberrant Hh signaling. This is due to the fact that Pdgfrα is a downstream Hh target gene, at 
least in BCC 
162
. In addition, it is possible that the overexpression of Pdgfrα and the lack of 
Kit expression reflect the origin of the tumors from a cell line that is different from the Kit
+
 
ICC (see below). 
 





 mice. This was not only revealed by the responsiveness of 
the tumors to imatinib, but also by phosphorylation of Pdgfrα in the tumors. In humans, 
aberrant PDGFRA pathway activity in GIST can be attributed to PDGFRA mutations or to 
an increased PDGF ligand expression 
161
. The latter could explain the Pdgfrα pathway 




 model.  
6.1.3 GIST-like tumors of PtchfloxfloxLysMcre+/- mice are derived from LysM+ cells of 
the intestine 
 
The LysMcre driver used in this study targets LysM-expressing cells, which up to date are 
considered to be mainly macrophages, DC and granulocytes 
104
. This, at first glance, would 
imply the origin of the GIST-like tumors from these cells which settled within the gut wall. 
Another possibility would be that a Ptch-deficient, LysM
+
 transplanted BM-derived HSC 
(which also can express LysM; see 2.5 of introduction) has settled into the normal intestine. 










 mice reconstituted with 




 mice, while not formally excluding, does not support 
these possibilities. It follows that the GIST-like tumors rather arose from non-myeloid cells 
that permit activation of the LysM promoter.  
The existence of such cells is indeed evidenced by the data presented in this study. Thus, we 
found rare LysM
+
 cells located between the serosa and the longitudinal muscle layer, or 
between the longitudinal and the circular muscle layers. Most importantly, using reporter 
mice, rare LysM-expressing cells were identified in the same localization where GIST-like 
tumors develop in consequence of the LysM-driven Ptch inactivation, i.e. between the serosa 
and the longitudinal muscle layer and between the longitudinal and circular muscle layer.  
6.1.4 GIST-like tumors of PtchfloxfloxLysMcre+/- mice are derived from Kit negative cells 
of the intestine 
 





are not derived from the Kit-positive ICC. This was revealed by a costaining of LysM-









mice) cells in 
the muscle layer co-expressed Pdgfrα (see results section Figure 21, middle panel). In 
contrast, we did not detect any distinct LysM-positive (i.e. LacZ-positive)
 
cells expressing 
Kit, but found that many LacZ-positive
 
and Kit-positive cells were juxtaposed (see results 
section Figure 21, right panel). 
In most instances human GIST are considered to originate from ICC, which have gain-of-
function mutations in KIT. ICC are mesenchymal cells located within the muscular wall of 
the gastrointestinal tract, where they actively propagate electrical slow waves in the GI 
























Although the co-expression of Pdgfrα in LysM-positive cells may be a coincidence, it is 
tempting to speculate that the LysM-expressing Pdgfrα-positive
 
cells may serve as an origin 




 mice. Together with the juxtaposition to the 
Kit-positive ICC, these cells
 
may represent a subset of the Pdgfrα-positive and Kit-negative 
fibroblast-like cells as reported by others 
61
. Alternatively, they could represent a subset of the 






is in agreement with the evidence suggesting that KIT and PDGFRA activity can replace each 
other during GIST progression in humans 
161




 mouse model is 
not only the first murine model in which endogenous GIST develop independently of Kit 
mutations, but also gives insights into the nature of the cell of origin of GIST different from 
ICC. 
6.1.5 GIST-like tumors of PtchfloxfloxLysMcre+/- mice may occur due to cooperation of 









 mice express increased levels of Hh target genes. Strikingly, the positive 
correlation between HH pathway genes and PDGFRA expression and mutational status is 
also observed in human GIST and thus seems to be a common phenomenon in this tumor.  
Our data provide evidence that activated Pdgfrα cooperates with Hh in tumor formation. 
This is suggested by the cooperative effect of activated PDGFRA signaling and of the HH 
target GLI1 on cellular transformation. To this end, we have analyzed the activation of 
PDGFRA, ERK and JUN in control and PDGFB-treated HaCaT cells. The data revealed a 
strong phosphorylation/activation of all 3 proteins after PDGFB-treatment. Since JUN 
phosphorylation is crucial for the cooperative transformation effect of active HH and 
receptor-tyrosine kinase signaling such as EGFR signaling 
116
, a similar mechanism can be 
assumed for active HH and PDGFRA signaling. Furthermore, the PDGFRA-mediated 
induction of JUN in our experimental setting may be similar to the situation in PDGFRA-
associated human GIST that show high expression of JUN 
128
. Admittedly, the aberrant 
activity of the Hh pathway in mouse GIST-like tumors results from the intended deletion of 
the Hh receptor and tumor suppressor Ptch. Notwithstanding the artificial nature of this 
manipulation, deletions of the PTCH locus or aberrant activity of the HH signaling pathway 
have been reported in up to 50% or 80% of GIST cases, respectively 
45, 46
. It follows that the 
mutational or otherwise activation of the HH pathway may be a driving and early event in 
the formation of human GIST. Alternatively, active PDGFRA signaling (e.g. due to a 
PDGFRA mutation) may stimulate GLI activity, as recently shown for signaling by EGFR 
112
.  
Taken together, we present a new model of GIST formation, which does not involve Kit 




These findings add to the accumulating lines of experimental evidence, revealing that an 
aberrant activation of HH signaling and RTK signaling, such as the EGFR signaling cascade, 
frequently cooperate during cancer initiation and progression. RTK signaling has been 
shown to cooperate with HH signaling through multiple cross-talks which results in the 
malignant transformation of cells and also can cause treatment resistance and disease 
relapse. For example, activity of GLI proteins can be modified by integration of distinct 
signals, such as the MEK/ERK and PI3K/AKT pathway in BCC by integration of the 
HH/GLI and EGFR pathway. It has been shown that both pathways synergistically induced 
oncogenic transformation, which was dependent on EGFR-mediated activation of the 
RAS/RAF/MEK/ERK but not of the PI3K/AKT pathway. Furthermore, EGFR/MEK/ERK 
signaling induced JUN activation, which was essential for oncogenic transformation in 
combination with the GLI activator forms GLI1 and GLI2. In addition, pharmacologic 
inhibition of EGFR and HH/GLI efficiently reduced growth of BCC cell lines derived from 
mice with activated HH/GLI signaling. These results identified the synergistic integration of 
GLI activator function and EGFR signaling as a critical step in oncogenic transformation 
112
. 
Due to these data, it is possible that oncogenic transformation due to the activation of both 
PDGFRA and HH signaling follows a similar mechanism. 
However, future studies are required to more precisely establish the molecular mechanisms 
and specific downstream signaling elements that may contribute to the cooperative or 
synergistic interactions of HH and PDGFRA signaling. It would also be of great therapeutic 
interest to define the potential interaction between PDGFRA and HH signaling in human 
GIST.  
6.1.6 Implications for GIST therapy 
 
GIST is the most common mesenchymal tumor affecting the GI tract and occurs with an 
annual frequency of 10 to 14.5 per million of the population
165
. Surgery is the standard of 
care for primary disease, whereas imatinib is recommended for first-line treatment of 
unresectable and/or metastatic GIST. Although imatinib and other tyrosine kinase inhibitors 
have improved survival of patients with advanced GIST, complete responses are rare. 
Primary resistance to imatinib occurs in 12–14% of patients and the majority of patients who 
initially benefit from tyrosine kinase inhibitors eventually become resistant, with a median 






Our data now implicate a role of HH signaling in GIST. Thus, GIST patients with HH 
pathway activation may benefit from combination treatment protocols that besides imatinib 
include an HH antagonist e.g. GDC-0449, which has recently been shown to exhibit 
antitumor activity in clinical studies 
167, 168
.  
6.2 Functional role of Ptch in the innate immune system  
 
In another line of this study, the role of Ptch-deficient macrophages and other myeloid cells 
such as granulocytes in inflammatory responses and tumor progression was examined. For 






 control mice were 
stimulated with the TLR agonists LPS and BLP, and the influence of the Ptch deletion on 
viability, cytokine expression and secretion, and proliferation was investigated. Then, in 
order to analyze the function of Ptch in myeloid cells during tumor surveillance, two different 






 mice. In addition, 
tumors were chemically induced in the skin of the animals, and the growth of the tumors was 
monitored. Furthermore, the infiltration of the tumor microenvironment with macrophages 
and granulocytes was investigated. Due to lack of time, some of the experiments were only 
done once, which hampers an explicit interpretation of the data. 
6.2.1 Role of Ptch in inflammatory responses after stimulation with TLR agonists 
 
Macrophages and granulocytes are important players in innate immunity. In addition to 
acting as a first line resistance against pathogens, these cells undergo reprogramming of their 
functional properties in response to signals derived from different stress or pathogen such as 
microbes or microbial moieties like LPS from gram-negative bacteria and BLP from gram-
positive bacteria 
169
. Since LPS and BLP are potent activators of monocytes and macrophages 
via stimulation of TLR4 and TLR1/2, respectively, these two compounds were used to 
analyze whether Ptch plays a role in regulating inflammatory responses. LPS and BLP have 
been shown to polarize the macrophages towards the M1 phenotype, which normally includes 






The data showed that Ptch has generally no effect on the cytokine production after 
stimulation with LPS. Thus, LPS stimulation of macrophages resulted in an increased 
secretion of pro-inflammatory cytokines TNFα, IL-6 and RANTES in a time-dependent 




12p40, and of the chemokines KC, MCP-1, MIP-1α. However, Ptch did not influence the 
secreted amount of these chemokines and cytokines, because no differences were detected 
when comparing the values derived from Ptch mutant or control BMDM. These data indicate 
that Ptch is probably dispensable for TLR4-mediated activation and production of 
macrophage-derived cytokines and chemokines.  
In contrast to LPS, the preliminary data suggest that BLP-stimulation may result in a stronger 
activation of the Ptch mutant BMDM when compared to the controls. This was revealed by 
qRT-PCR of the pro-inflammatory cytokine IL-6, which appeared upregulated in Ptch mutant 
BMDM after the BLP stimulus. However, the expression levels of RANTES and TNFα in 
Ptch mutant and control BMDM were not different. Since this experiment was only 
performed once, and since IL-6 secretion by ELISA was not examined, these results have to 
be regarded with reservation. If IL-6 is indeed upregulated in BLP-stimulated Ptch mutant 
BMDM, it is possible that Ptch modulates TLR1/2-mediated signaling. The modulation 
would be specific for the TLR1/2 pathway, because Ptch did not influence TLR4-mediated 
signaling i.e. IL-6 expression after stimulation with LPS. 
 
Furthermore, the viability and proliferation of Ptch mutant and control BMDM after exposure 
to BLP and/or LPS was examined. Cell viability was not affected when the cells were 
incubated with LPS for 6, 12, and 24 hours. Unfortunately, the results for a longer exposure 
(i.e. 48 h and 72 h) and for the exposure to BLP are not available yet. However, the BrdU-
incorporation assay revealed that the amount of incorporated BrdU decreased in both Ptch 
mutant and control BMDM after a 72 h and a 48 h exposure to LPS and BLP, respectively. 
Most interestingly, the decrease in BrdU incorporation was more pronounced in Ptch control 
macrophages when compared to the Ptch mutant BMDM. These data indicate that Ptch 
mutant BMDM are more resistant to LPS- and BLP-treatment. Whether this is due to an 
increased proliferation rate or to a decreased apoptosis rate or to a resistance to general 
toxicity of the mutant cells is hard to say. For this purpose, cell viability at these time points 
(i.e. after 72 h or 48 h of stimulation with LPS or BLP, respectively) as well as the apoptosis 
rate must be analysed.  
Although these data are preliminary, it is tempting to speculate that the observed protection 
from apoptosis and or toxicity due to BLP stimulation may contribute to the increased IL-6 
expression of the Ptch-deficient macrophages. It is known that IL-6 operates to control the 
magnitude of inflammatory responses 
173




interesting to investigate how Ptch regulates the BLP-mediated modulation of IL-6 
expression, and whether this regulation involves TLR1/2 signaling and is specific for said 
signaling. 
 







 mice suggests that Ptch-deficiency did not result in 
activation of the Hh signaling pathway (i.e. Gli1 and Ptch expression) in these cells. This 
suggests that the differences between Ptch mutant and Ptch wt BMDM after LPS and BLP 
stimulation are independent of Hh signaling activity. However, more experiments are needed 
to confirm this suggestion, e.g. it would be important to investigate Hh signaling activity in 
cells after stimulation with LPS or BLP. 
6.2.2 The role of Ptch in tumor immune surveillance  
 
Tumors consist of neoplastic cells and non-malignant stromal cells. The development of 
tumors is regulated by interactions between the neoplastic cells and their microenvironment. 
The interactions between tumor cells and cells of the immune system are extremely complex. 
The outcome of such interactions can span all scenarios from suppression of tumor growth by 
to enhancement of tumor progression by the immune system 
174
. 
Residential macrophages have early contact with the arising tumor. Tumor-associated 
macrophages can have different functions according to their physiological or 
pathophysiological context and can be associated with poor prognosis and tumor progression 
72
. As already stated in the introduction, macrophages are able to secrete growth factors, 
cytokines and chemokines. The secretion of the respective cytokines is dependent on local 
stimuli such as cytokines, the engagement of adhesion molecules, or interaction with 
pathogens. According to their activation state, receptor expression, cytokine production, and 
functions, macrophages have been broadly classified in the M1 or M2 type. "Classically 
activated" M1 macrophages, which are activated by microbial products or IFN-γ, produce 
large amounts of proinflammatory cytokines and are implicated in the killing of tumor cells. 
M1 macrophages usually express the Th1 cell–attracting chemokines such as CXCL9 and 
CXCL10 and release large amounts of proinflammatory cytokines such as IL-12, IL-23 and 
TNFα. They usually produce reactive nitrogen and reactive oxygen intermediates and show a  
higher expression of major histocompatibility complex (MHC) class II molecules 
171
. In 




anti-inflammatory responses. They also promote angiogenesis and generally have a tumor-
promoting effect 
72
. The M2 phenotype is shared by tumor-associated macrophages and is 
characterized by the expression of e.g. Arg1 and Trem2. The phenotype of a macrophage 
population can change over time, like in tumor progression where the macrophage phenotype 
can change from M1 to M2 
72
. We have started to analyze the involvement of Ptch in 
determining a) the fate of macrophages and b) the numbers of macrophages and other cells 
from the immune system during tumor development.  
 






 control mice on a C57BL/6 background 
were transplanted with the syngeneic melanoma cell line B16F10, both by subcutaneous and 
intravenous injection, to obtain locally growing and “metastatic” tumors, respectively. 
Transplanted mice were all younger than 10 weeks to avoid a potential modulation of the 









 mice is not 
known, most of the GIST-like tumors became phenotypically conspicuous at around 25 to 26 
weeks of age). As demonstrated by the experiments, Ptch-deficient macrophages and other 
Ptch-deficient myeloid cells did neither influence growth nor metastasis in this model. 
However, because the B16F10 cell line is fast-growing, it may be possible that subtle 
differences in tumor growth and progression were overlooked. Therefore, we repeated this 
experiment with the slow-growing ovarian carcinoma cell line ID8-LUC, which is derived 
from a transformed late-passage mouse ovarian surface epithelium from adult C57BL6 mice 
and which was stably transfected with luciferase by lentiviral infection. These cells were 
injected i.p.. The in vivo tumor growth was monitored by injecting D-luciferin, and the 
bioluminescence was monitored by a CCD camera. As previously reported, all the injected 
animals displayed multiple tumors throughout the peritoneum, which covers the peritoneal 
cavity, the diaphragm, and all other intraperitoneal organs 
119
. Nevertheless, as already seen 





 when compared to Ptch
flox/flox 
control mice. However, as already stated 
in the results section, the growth of ID8-LUC cells seemed to cease in Ptch
flox/flox 
mice at 
week 7 after transplantation. Because implantation of ID8-LUC cells causes progressive 








In addition, transplantation of ID8-LUC cells can result in ascites. Indeed, ascites developed 






control mice. The 
occurrence of ascites is associated with late-stage ovarian cancer and is due to an abnormal 
collection of fluid with a cellular fraction consisting mainly of cancer cells, lymphocytes, and 
mesothelial cells in the peritoneal cavity 
175, 176
. The cell composition of the ascites can give 
some clues about the status of the “tumor microenvironment”. For example, it was shown that 
a subset of tumor-associated macrophages expressing B7-H4 was significantly increased in 
the ascites of human ovarian carcinoma. These tumor-associated macrophages were 
furthermore shown to inhibit the proliferation and activity of T cells 
177
. Thus, the phenotype 
and the number of cells present in the tumor microenvironment are crucial in their 
contribution to the tumor immune response.  
Our preliminary data showed that the Ptch-deficiency probably does not influence the cellular 
composition of the ascites, meaning that there is no gross difference between the genotypes. 
This was revealed by the analysis of the expression of the M2 macrophage markers, Arg1 and 
Trem2. Increased expression of these two genes would indicate not only the M2-phenotype, 
but would also indicate an increased number of macrophages and MDSC expressing these 
genes. Unfortunately, due to the high number of erythrocytes, the analysis of the cellular 
composition of the ascites by flow cytometry was not possible. These experiments would be 
crucial to learn more about the recruitment of different cell types in the tumor environment 
and will be performed in the future. 
Nevertheless, splenic MDSC, macrophages and granulocytes were analyzed. The rationale 
for the analysis was the fact that the spleen acts as a reservoir of myeloid cells, which can be 
mobilized to amplify the tumor-associated neutrophils (granulocytes), tumor-associated 
macrophages, and MDSC responses on tumor recruitment. Also, HSC and GMP accumulate 
in large numbers within the splenic red pulp of tumor-bearing mice. These cells establish 
niches of proliferation, produce new MDSC locally, and participate in the continuous 
replenishment of the myeloid cell reservoir 
147
. Therefore, and as previously shown 
147
, we 
expected that the counts of these splenic cells will mirror the number of these cells in the 
ascites of the ID8-LUC transplanted animals. The analysis revealed that the Ptch-deficiency 
did not impact the number of splenic MDSC, macrophages or granulocytes. 
 
MDSC are a heterogeneous population of cells that consist of myeloid progenitors and 




and the spleen of tumor-bearing animals. These cells have been reported to regulate innate 
immune responses by modulating the cytokine production of mature macrophages. In 
addition, they play a role in tumor angiogenesis, tumor cell invasion, and metastasis 
178
. 
MDSC also express high levels of Arg1 and act as immunosuppressors during tumor growth. 
Arg1 produced by MDSC can impair T cell function in tumor-bearing animals by decreasing 
the expression of the TCR zeta chain. Thus, MDSC apparently interfere with the T cell 
antigen receptor, so that there is no signal to activate the T cells 
178














 mice when compared to tumor-bearing control mice, and since Arg1 
expression levels were not increased in the “tumor microenvironment” (as judged by qRT-
PCR analysis of mRNA derived from ascites), Ptch apparently is not necessary for 
stimulation of MDSC. Ptch is also not necessary for the elevation of numbers of MDSC, 
granulocytes or macrophages, at least in the spleen. Furthermore, these results also indicate 




 mice did not alter the 
number of splenic cells derived from the myeloid lineage.  
 
Another approach to study the role of Ptch in tumor immune surveillance was the chemical 




 mice. With respect to the following data it 
should be mentioned that these results are considered reliable. 
The mouse skin chemical carcinogenesis model has been widely used to study initiation, 
promotion, and progression (malignant conversion) of mouse skin tumors. The initiation of 
the tumors is achieved through a single topical application of DMBA. This causes a genetic 
mutation in the stem cell or progenitor cell compartment, which is either an activating 
mutation in a proto-oncogene such as H-ras or an inactivating mutation in a tumor suppressor 
gene such as p53. Repeated exposure of the skin to chemical tumor promoters like TPA (or 
other irritants) promotes the expansion of the initiated cell and a generalized epidermal 
hyperplasia. The initiated cells can further outgrow the normal epidermal cells to form 
premalignant papillomas. Due to further genetic changes, some of the papillomas convert to 
malignant carcinomas capable of invading through the basement membrane and finally 
metastasizing to the lymph nodes and lungs 
179
. In addition, the two-stage chemical 
carcinogenesis protocol can result in melanoma-like nevi and BCC-like structures 
180
. 
Furthermore, is well known that the immune system plays a role in the occurrence of 




epidermal tumorigenesis likely through a T cell–dependent induction of keratinocyte 
proliferation 
181
. In addition, DMBA/croton-oil-associated melanoma does not occur in mice 
deficient for TLR4 (information: as TPA, croton-oil is a phorbol-derivative) 
182
. Furthermore, 
and most interestingly, DMBA/TPA-treated mice deficient in Langerhans Cells (LC) develop 








 mice the numbers and the 





 mice was more hyperplastic, which was accompanied by 
an increased, although not significant, number of Ki-67
+
 cells when compared to the controls. 




 mice were larger than those induced 
in Ptch
flox/flox
 control mice and microscopically resembled melanoma. Furthermore, these 





but a decrease in CD3
+
 cells when compared to the controls.  
 
These data suggest that a Ptch-deficiency in macrophages and in other myeloid cells in the 
tumor microenvironment enhances keratinocyte proliferation in DMBA/TPA treated skin, but 
does not influence the initiation or progression of tumors derived from the epidermal skin 




 mice seems to 
increase the size of DMBA/TPA-associated nevi, but not their numbers. This suggests that 





 mice, the area of “melanoma-like” tumors was strongly 
surrounded with F4/80
+
 cells. In addition, the tumor surrounding also showed an increased 
number of MHCII
+









The main role of DC is to induce specific immunity against invading pathogens while 
maintaining tolerance to self-antigens. As described previously by Norian and colleagues, DC 
play a critical role in the outcome of adaptive immune responses against growing tumors. 
While it is generally assumed that the presence of mature DC should promote protective anti-
tumor immunity, evidence to the contrary does exist. Thus, Norian and colleagues showed 
that tumor-infiltrating DC actively contribute to the suppression of protective CD8
+
 T cell-




Furthermore, tumor-infiltrating DC were found in every murine tumor type including 
transplanted fibrosarcoma and breast carcinoma cell lines and spontaneously developing 
mammary tumors 
185
. Based on these data the authors hypothesized that tumors can induce 
matured tumor-infiltrating DC to act as potent suppressors of T cell-based antitumor 
immunity.  
 
LC are a myeloid subset of tissue DC located in the epidermis 
186
 and constitutively express 
MHCII 
187
. Immature LC residing in the epidermis can collect antigen, and upon various 
stimuli, they mature and migrate to draining LN 
188
, where they can directly present antigen 
secreted from keratinocytes 
189
. Thus, they are presumed to play a key role in promoting 
immune responses.  
LC have traditionally been thought to stimulate adaptive immunity. Indeed, LC have been 
shown to present antigens to activate the CD4 helper T cell and CD8 cytotoxic T cell 
compartments, including potent antitumor effector cells. However, emerging data have also 
revealed that LC might suppress T cell function, and that LC might contribute to cutaneous 
responses that facilitate keratinocyte transformation and growth of papilloma and SCC 
(reviewed in 
190
). Indeed, mice deficient in LC are almost completely resistant to papilloma 
and carcinoma formation by this two-stage carcinogenesis protocol 
183
. It is thought that LC 
might have the capacity to internalize and metabolize and increase mutagenicity of 
polyaromatic hydrocarbons such as DMBA. Moreover, it is speculated that LC might 
influence the growth of mutated epidermal cells, for example via the local production of 
growth factors or anti-apoptotic factors (reviewed in 
190
). In contrast, and to our best 
knowledge, a role of LC in DMBA/TPA-induced nevi/melanoma-formation has not been 
reported so far. However, LC seem to play a very important role in human melanoma. Thus, 
it has been reported that LC were significantly increased around in situ and early-invasive 









 mice:  




 mice did not result in promotion of papilloma 
growth. This indicates that the Ptch-deficiency in myeloid cells apparently did not promote 
the growth of “initiated” keratinocytes, i.e. those keratinocytes that could give rise to 








the Ptch-deficiency apparently promoted the proliferation of the “normal” keratinocytes. 
Thus, one could speculate that the role of Ptch in skin macrophages such as dermal 
macrophages, DC and LC, is to prevent hyperproliferation of “normal” keratinocytes. Why 
the growth of “initiated” keratinocytes was not prevented is hard to explain. In addition, Ptch 
in skin macrophages may be a necessary factor to prevent proliferation of melanocytic cells. 




 cells in and around the nevi, ii) the 
decrease in CD3
+





 mice, one can speculate that DC and LC in the melanoma-like areas in 
mutant mice contribute to a tumor escape mechanism. This would fit very nicely to the 
above-mentioned observations that tumor-infiltrating DC inhibit T cell migration and 
proliferation and thus act as potent suppressors of T cell-based antitumor immunity 
185
. It also 
fits the observation that LC seem necessary for the promotion of in situ and early-stage 
melanoma in humans 
191
. Together one could speculate that role of Ptch in skin macrophages 
such as DC and LC are to prevent proliferation of “normal” keratinocytes and of 
preneoplastic melanocytes.  
 




 mice resulted in an increase 
of the DC and LC in the tumor area is hard to explain. However, it is possible that Ptch is a 
factor necessary for migration of skin macrophages including DC and LC to the tumor area. 
In other words, it is possible that Ptch mutant macrophages showed a higher migratory 
capacity than Ptch-wt macrophages because they were either hypo- or hyper-responsive to 
chemokine that could be produced by the preneoplastic melanocytes. Indeed, melanoma cells 
can produce the macrophage migration inhibitory factor MIF 
192
. Therefore it is possible that 
Ptch-deficient macrophages just do not respond to this factor. On the other hand, melanoma 
also produces factors that result in macrophage-recruitment to the tumors. One example is 
Thrombospondin-1, which is produced by melanoma cells and is a very potent attractant for 
macrophages 
193, 194
. Therefore, it is possible that Ptch-deficient macrophages are 
hyperreactive to those factors and migrate to the melanoma-like lesions. Whether this is true 
or not remains to be established in the future. 
 
In summary, our data strongly suggest that Ptch in myeloid cells such as skin macrophages is 
an important factor in the immune surveillance of melanoma. However, more experiments are 




6.3 Outlook on the future studies on the role Ptch in macrophages and other cells 
derived from the myeloid lineage 
 
Many data presented in the second part of this study are preliminary results. The only results 





 mice and Ptch
flox/flox
 control mice. 
It will be important to repeat the experiments to show that the increase of IL-6 after TLR1/2-
mediated (i.e. BLP-mediated) stimulation as well as the higher BrdU incorporation rate after 
BLP- and LPS-stimulation are “real” characteristics of Ptch mutant BMDM. With respect to 
BrdU incorporation it will be interesting to see whether this indeed reflects a higher 
proliferation rate or rather a resistance to apoptosis. Furthermore, the effects of BLP and LPS 




 mice. If BLP indeed modulates IL-6 
expression/secretion as well as the proliferation/apoptosis rate of Ptch mutant macrophages, it 





 mice treated with the substance. Indeed, mice heterozygous for a Ptch 
mutation have been reported to be more responsive to systemic LPS treatment.
195
, which 
could be related to cells derived of the myeloid lineage. 
 




 mice develop 





cells but decreased numbers of CD3
+
 cells, must be followed up. Furthermore, there are still 
several questions that need to be answered. While we have high recombination efficiency at 
the Ptch locus of BMDM, PM and splenic macrophages, we have not looked at the 
recombination efficiency in tissue macrophages of the skin. The first question is whether 




 mice are indeed Ptch knock-out and whether 
these knock-out cells show active Hh signaling. This question can be answered by Ptch 
recombination assay and in situ hybridization assay using Ptch and/or Gli1 probes. 
The second question is whether Ptch mutant macrophages have increased migratory capacity 
towards melanoma cells. This could be answered by macrophage/melanoma cell co-culture 
in a Boyden chamber or Transwell migration assay. If there is an increase in the migratory 
capacity of Ptch mutant macrophages, this could explain the increased presence of F4/80
+
 














these mice are larger, one would certainly expect that they are rather M2- than M1-like. If so, 
then it would also be important to know by which mechanism the Ptch mutation is 
influencing the macrophage phenotype and the tumor immune response.  
Unraveling the exact function of Ptch in macrophages during the tumor immune response 
may provide a basis for the better understanding of melanoma pathogenesis and the role of 
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